Benign neoplasm
MONDO:0005165A neoplasm which is characterized by the absence of morphologic features associated with malignancy (severe cytologic atypia, tumor cell necrosis, and high mitotic rate). Benign neoplasms remain confined to the original site of growth and do not metastasize to other anatomic sites.
Also known as: benign neoplasm, benign neoplasm (disease), neoplasm (disease), benign, benign tumor, benign tumour, benign unclassifiable tumor, benign unclassifiable tumour, cell type benign neoplasm
2108 clinical trials for this condition and its sub-types, 13 tagged with Benign neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Benign neoplasm
-
Musculoskeletal system benign neoplasm 0 trials · 224 incl. sub-types
8 sub-types
- Benign muscle neoplasm 4 trials · 118 incl. sub-types Sub-types →
- Benign connective and soft tissue neoplasm 0 trials · 101 incl. sub-types Sub-types →
- Chondroma 4 trials Sub-types →
- Ameloblastoma 2 trials Sub-types →
- Benign neoplasm of gum 0 trials Sub-types →
- Benign neoplasm of sternum 0 trials
- Benign skeletal muscle neoplasm 0 trials
- Benign uterine ligament neoplasm 0 trials
-
Integumentary system benign neoplasm 0 trials · 120 incl. sub-types
8 sub-types
- Benign neoplasm of skin 3 trials · 117 incl. sub-types Sub-types →
- Adiposis dolorosa 2 trials
- Intraductal breast papilloma 1 trial Sub-types →
- Bartholin gland benign neoplasm 0 trials Sub-types →
- Adenoma of nipple 0 trials
- Familial multiple lipomatosis 0 trials
- Hemangioma of subcutaneous tissue 0 trials
- Multiple symmetric lipomatosis 0 trials Sub-types →
-
Benign reproductive system neoplasm 0 trials · 117 incl. sub-types
6 sub-types
- Benign female reproductive system neoplasm 5 trials · 117 incl. sub-types Sub-types →
- Adrenal rest tumor 0 trials
- Benign male reproductive system neoplasm 0 trials Sub-types →
- Benign neoplasm of pituitary gland 0 trials
- Paratesticular lipoma 0 trials Sub-types →
- Sex cord-stromal benign neoplasm 0 trials Sub-types →
-
Cardiovascular organ benign neoplasm 0 trials · 114 incl. sub-types
9 sub-types
- Benign blood vessel neoplasm 0 trials · 103 incl. sub-types Sub-types →
- Lymphangioma 5 trials · 15 incl. sub-types Sub-types →
- Benign choroid plexus neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Benign neoplasm of choroid 0 trials Sub-types →
- Benign neoplasm of heart 0 trials Sub-types →
- Benign neoplasm of pericardium 0 trials Sub-types →
- Cerebrovascular benign neoplasm 0 trials
- Intravascular angioleiomyoma 0 trials
- Vasoproliferative tumor of retina 0 trials
-
Benign epithelial neoplasm 0 trials · 106 incl. sub-types
25 sub-types
- Benign epithelial skin neoplasm 0 trials · 29 incl. sub-types Sub-types →
- Craniopharyngioma 29 trials Sub-types →
- Adrenal cortex adenoma 12 trials · 19 incl. sub-types Sub-types →
- Papilloma 2 trials · 8 incl. sub-types Sub-types →
- Follicular thyroid adenoma 1 trial · 7 incl. sub-types Sub-types →
- Parathyroid gland adenoma 6 trials Sub-types →
- Kidney oncocytoma 3 trials Sub-types →
- Ameloblastoma 2 trials Sub-types →
- Hepatocellular adenoma 2 trials Sub-types →
- Warthin tumor 1 trial
- Renal adenoma 0 trials · 1 incl. sub-types Sub-types →
- Bartholin gland adenoma 0 trials
- Bartholin gland adenomyoma 0 trials
- Benign adrenal gland pheochromocytoma 0 trials
- Benign basal cell neoplasm 0 trials
- Benign breast adenomyoepithelioma 0 trials
- Benign mesonephroma 0 trials
- Benign ovarian mucinous tumor 0 trials
- Breast adenoma 0 trials Sub-types →
- Lung adenoma 0 trials Sub-types →
- Middle ear adenoma 0 trials
- Minor vestibular glands adenoma 0 trials
- Mucinous adenofibroma 0 trials Sub-types →
- Ovarian adenoma benign 0 trials Sub-types →
- Prostatic adenoma 0 trials
-
Nervous system benign neoplasm 0 trials · 87 incl. sub-types
5 sub-types
- Central nervous system organ benign neoplasm 1 trial · 57 incl. sub-types Sub-types →
- Sensory organ benign neoplasm 0 trials · 20 incl. sub-types Sub-types →
- Hemangioblastoma 9 trials · 10 incl. sub-types Sub-types →
- Neurocutaneous melanocytosis 1 trial
- Phakomatosis pigmentokeratotica 0 trials
-
Benign urinary system neoplasm 50 trials · 62 incl. sub-types
6 sub-types
- Kidney benign neoplasm 4 trials · 12 incl. sub-types Sub-types →
- Ureter benign neoplasm 1 trial Sub-types →
- Benign prostate phyllodes tumor 0 trials
- Benign urethral neoplasm 0 trials Sub-types →
- Bladder benign neoplasm 0 trials Sub-types →
- Urothelial papilloma 0 trials Sub-types →
-
Benign endocrine neoplasm 0 trials · 60 incl. sub-types
14 sub-types
- Benign thyroid gland neoplasm 21 trials · 26 incl. sub-types Sub-types →
- Benign neoplasm of adrenal gland 0 trials · 19 incl. sub-types Sub-types →
- Benign neoplasm of parathyroid gland 0 trials · 6 incl. sub-types Sub-types →
- Liver hemangioma 6 trials Sub-types →
- Hepatocellular adenoma 2 trials Sub-types →
- Pineocytoma 1 trial
- MAX-related tumor predisposition 0 trials
- TMEM127-related tumor predisposition 0 trials
- Benign carotid body paraganglioma 0 trials
- Benign neoplasm of pituitary gland 0 trials
- Benign neoplasm of thymus 0 trials Sub-types →
- Bile duct papillary neoplasm 0 trials Sub-types →
- Liver leiomyoma 0 trials Sub-types →
- Liver lipoma 0 trials Sub-types →
-
Pheochromocytoma 59 trials
2 sub-types
- MAX-related tumor predisposition 0 trials
- TMEM127-related tumor predisposition 0 trials
-
Benign digestive system neoplasm 0 trials · 41 incl. sub-types
10 sub-types
- Pleomorphic adenoma 12 trials
- Hepatobiliary benign neoplasm 2 trials · 8 incl. sub-types Sub-types →
- Benign neoplasm of pancreas 7 trials Sub-types →
- Intestinal benign neoplasm 1 trial · 7 incl. sub-types Sub-types →
- Benign neoplasm of esophagus 3 trials Sub-types →
- Benign neoplasm of stomach 1 trial · 2 incl. sub-types Sub-types →
- Hepatocellular adenoma 2 trials Sub-types →
- Benign neoplasm of gallbladder 0 trials Sub-types →
- Benign neoplasm of oropharynx 0 trials
- Bile duct papillary neoplasm 0 trials Sub-types →
-
Thoracic benign neoplasm 0 trials · 22 incl. sub-types
8 sub-types
- Breast benign neoplasm 11 trials · 20 incl. sub-types Sub-types →
- Lung benign neoplasm 1 trial · 2 incl. sub-types Sub-types →
- Benign axillary neoplasm 0 trials Sub-types →
- Benign neoplasm of chest wall 0 trials Sub-types →
- Benign neoplasm of heart 0 trials Sub-types →
- Benign neoplasm of mediastinum 0 trials Sub-types →
- Benign neoplasm of pericardium 0 trials Sub-types →
- Benign neoplasm of sternum 0 trials
-
Benign perivascular tumor 0 trials · 18 incl. sub-types
4 sub-types
- Myofibroma 17 trials
- Infantile myofibromatosis 1 trial Sub-types →
- Angioleiomyoma 0 trials Sub-types →
- Glomangiomatosis 0 trials
-
Respiratory system benign neoplasm 1 trial · 8 incl. sub-types
15 sub-types
- Benign laryngeal neoplasm 1 trial · 2 incl. sub-types Sub-types →
- Benign neoplasm of trachea 0 trials · 2 incl. sub-types Sub-types →
- Lung benign neoplasm 1 trial · 2 incl. sub-types Sub-types →
- Benign neoplasm of nasal cavity 1 trial Sub-types →
- Benign neoplasm of ethmoidal sinus 0 trials Sub-types →
- Benign neoplasm of frontal sinus 0 trials Sub-types →
- Benign neoplasm of hypopharynx 0 trials Sub-types →
- Benign neoplasm of maxillary sinus 0 trials Sub-types →
- Benign neoplasm of nasopharynx 0 trials
- Benign neoplasm of oropharynx 0 trials
- Benign neoplasm of pleura 0 trials Sub-types →
- Benign neoplasm of sphenoidal sinus 0 trials Sub-types →
- Benign neoplasm of tonsil 0 trials Sub-types →
- Endobronchial lipoma 0 trials
- Paranasal sinus Schneiderian papilloma 0 trials Sub-types →
-
Benign neoplasm of salivary gland 1 trial · 5 incl. sub-types
3 sub-types
- Benign neoplasm of major salivary gland 0 trials · 3 incl. sub-types Sub-types →
- Warthin tumor 1 trial
- Benign neoplasm of minor salivary gland 0 trials
-
Benign chondrogenic neoplasm 0 trials · 4 incl. sub-types
3 sub-types
- Chondroma 4 trials Sub-types →
- Chondroblastoma 0 trials
- Chondromyxoid fibroma 0 trials
-
Benign neoplasm of oral cavity 1 trial
3 sub-types
- Adenomatoid odontogenic tumor 0 trials
- Benign neoplasm of hard palate 0 trials
- Benign neoplasm of soft palate 0 trials
-
Benign mastocytoma 0 trials
-
Benign mesenchymoma 0 trials
-
Benign mesothelioma 0 trials
5 sub-types
- Benign peritoneal mesothelioma 0 trials
- Epididymal adenomatoid tumor 0 trials
- Fallopian tube adenomatoid tumor 0 trials
- Pleural adenomatoid tumor 0 trials
- Uterine corpus adenomatoid tumor 0 trials
-
Benign neoplasm of buccal mucosa 0 trials
1 sub-type
- Papilloma of buccal mucosa 0 trials
-
Benign neoplasm of floor of mouth 0 trials
-
Benign neoplasm of lip 0 trials
-
Benign neoplasm of neck 0 trials
-
Benign neoplasm of pharynx 0 trials
4 sub-types
- Benign neoplasm of hypopharynx 0 trials Sub-types →
- Benign neoplasm of nasopharynx 0 trials
- Benign neoplasm of oropharynx 0 trials
- Benign neoplasm of tonsil 0 trials Sub-types →
-
Benign phyllodes tumor 0 trials
2 sub-types
- Benign breast phyllodes tumor 0 trials
- Benign prostate phyllodes tumor 0 trials
-
Calcifying fibrous tumor 0 trials
-
Germ cell benign neoplasm 0 trials
1 sub-type
- Benign teratoma 0 trials
-
Immune system organ benign neoplasm 0 trials
3 sub-types
- Benign neoplasm of lymph node 0 trials
- Benign neoplasm of spleen 0 trials Sub-types →
- Benign neoplasm of thymus 0 trials Sub-types →
-
Peritoneal benign neoplasm 0 trials
3 sub-types
- Benign peritoneal mesothelioma 0 trials
- Benign peritoneal solitary fibrous tumor 0 trials
- Disseminated peritoneal leiomyomatosis 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 964 trials in this tab.
-
Off-the-Shelf immune cells target solid tumors
Cure Recruiting nowResearchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …
Phase 1/2 • Sponsor: Ever Supreme Bio Technology Co., Ltd. • Aim: Cure
Last updated Sep 11, 2026 00:00 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Vaccine Recruiting nowThis study tests a personalized vaccine created from a patient's own immune cells (dendritic cells) that are trained to attack unique markers on their tumor. It is for people with advanced solid tumors who have not responded to standard treatments. The main goal is to check safet…
Sponsor: Fudan University • Aim: Vaccine
Last updated Jun 27, 2026 12:04 UTC
-
Experimental biologic AWT020 put to the test in Hard-to-Treat cancers
Disease control Recruiting nowResearchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…
Phase 1 • Sponsor: Anwita Biosciences • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug HMPL-A580 enters human trials
Disease control Recruiting nowThis early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…
Phase 1/2 • Sponsor: Hutchmed • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug trial aims to shrink painful lymphatic growths in kids and adults
Disease control Recruiting nowThis study tests alpelisib, a drug that targets a specific gene mutation (PIK3CA), in people with lymphatic malformations—abnormal growths of lymph vessels. The trial includes children and adults and compares alpelisib to a placebo to see if it can shrink the growths and ease sym…
Phase 2/3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill NP-101 tested in patients with Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody combo shows promise in early cancer trial
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…
Phase 1/2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug cocktail aims to outsmart advanced cancers
Disease control Recruiting nowThis early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New bispecific antibody D3L-002 enters first human trial for Hard-to-Treat cancers
Disease control Recruiting nowThis Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…
Phase 1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug DS3610a enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cancer drug YL217 enters first human tests
Disease control Recruiting nowThis early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…
Phase 1 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug targets Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…
Phase 1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…
Phase 1/2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
First-in-Human trial asks whether HG381 is safe and tolerable in advanced solid tumors
Disease control Recruiting nowResearchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…
Phase 1 • Sponsor: HitGen Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New cancer drug GI-108 enters human trials for advanced tumors
Disease control Recruiting nowThis study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …
Phase 1/2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy takes on advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…
Phase 1/2 • Sponsor: Hefei Xinzhu Biological Technology Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug cocktail aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…
Phase 1/2 • Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental injection SHR-7787 put to the test against advanced solid tumors
Disease control Recruiting nowResearchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…
Phase 1/2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a pill shrink Hard-to-Treat ovarian tumors?
Disease control Recruiting nowResearchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…
Phase 1/2 • Sponsor: Heronova Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a pill turn on genes that stop cancer? new trial begins
Disease control Recruiting nowThis early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…
Phase 1 • Sponsor: Accent Therapeutics • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: drug targets MTAP deletion
Disease control Recruiting nowThis phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
DNA-Guided immunotherapy trial aims to match drug to tumor
Disease control Recruiting nowThis study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…
Phase 2 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill shows promise in early trial for tough cancers
Disease control Recruiting nowThis early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…
Phase 1/2 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a smart drug deliver a toxic payload directly to cancer cells?
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…
Phase 1 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can steroids help cancer patients resume a promising therapy?
Disease control Recruiting nowThis study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Cancer patients on targeted therapy get extended safety monitoring
Disease control Recruiting nowThis study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug DXP-106 enters early human testing
Disease control Recruiting nowThis early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…
Phase 1 • Sponsor: Singlomics Biopharmaceuticals Zhuhai Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Nasal spray could deliver brain tumor treatment directly to Kids' tumors
Disease control Recruiting nowThis early-phase trial tests a nasal spray called NEO100 (a purified natural compound) in 12 children with certain aggressive brain tumors. The goal is to see if it's safe, find the best dose, and check if the drug reaches the tumor. Participants will receive increasing doses, an…
Phase 1 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug QLC5508 enters first human safety tests
Disease control Recruiting nowThis early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…
Phase 1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug BI 3810944 enters first human tests
Disease control Recruiting nowThis early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug ART6043 enters human trials for advanced tumors
Disease control Recruiting nowThis study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…
Phase 1/2 • Sponsor: Artios Pharma Ltd • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill targets HER2 cancers in phase 2 trial
Disease control Recruiting nowThis study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: first human trial of BGB-58067 begins
Disease control Recruiting nowThis early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New cancer drug targets two proteins at once in early trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug BG-C477 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a radioactive 'Smart Bomb' target tough tumors?
Disease control Recruiting nowResearchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …
Early phase 1 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…
Phase 1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Sound waves zapping liver tumors: new study tracks Real-World success
Disease control Recruiting nowThis study is collecting information on how well the HistoSonics Edison System, which uses sound waves (histotripsy) to destroy liver tumors, works in everyday medical practice. Up to 5,000 adults with liver tumors will be followed for up to 5 years after treatment. The main goal…
Sponsor: HistoSonics, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Experimental biologic M1-c6v1 put to the test in Hard-to-Treat solid tumors
Disease control Recruiting nowResearchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…
Phase 1 • Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Triple-Action antibody takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Virus-Based therapy offered to bladder cancer patients who failed standard care
Disease control Expanded accessThis program provides early access to cretostimogene grenadenorepvec, a virus-based therapy, for patients with non-muscle invasive bladder cancer that has not responded to standard BCG treatment. Eligible participants have a specific type of bladder cancer (CIS with or without hi…
Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug MK-8294 tested in patients with advanced cancers
Disease control Recruiting nowThis early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug SKB118 aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…
Phase 1/2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo may help bladder cancer patients keep their bladder
Disease control Recruiting nowThis study tests whether two drugs, enfortumab vedotin and pembrolizumab, can control muscle-invasive bladder cancer without needing to remove the bladder. About 390 adults whose cancer hasn't spread outside the bladder will receive either the drug combo or standard chemoradiatio…
Phase 3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control Recruiting nowThis study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New biologic drug GEN1106 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Experimental biological therapy VRT106 put to the test in advanced solid tumors
Disease control Recruiting nowResearchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…
Phase 1 • Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New cancer drug KK2269 enters first human tests
Disease control Recruiting nowThis early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…
Phase 1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug FORX-428 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …
Phase 1 • Sponsor: FoRx Therapeutics AG • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for advanced cancer? early trial tests MK-3120
Disease control Recruiting nowThis study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug SHR-4610 tested in patients with Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…
Phase 1/2 • Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New combo therapy aims to shrink advanced tumors
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a new pill shrink Hard-to-Treat tumors?
Disease control Recruiting nowThis trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…
Phase 1/2 • Sponsor: Lamassu Bio Inc • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody GEN1079 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug SGT003 put to the test against Hard-to-Treat solid tumors
Disease control Recruiting nowResearchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…
Phase 1/2 • Sponsor: Beijing Sungen Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New targeted drug enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…
Phase 1 • Sponsor: Adcendo ApS • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New cancer drug AGX101 enters human trials for advanced tumors
Disease control Recruiting nowThis early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…
Phase 1 • Sponsor: Angiex, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug GEN1119 aims to fight solid tumors that resist standard care
Disease control Recruiting nowThis trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
BioNTech launches first human test of BNT317 against advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat breast cancers
Disease control Recruiting nowThis early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New cancer drug FID-022 enters first human trial
Disease control Recruiting nowThis early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …
Phase 1 • Sponsor: Fulgent Pharma LLC. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a Two-Drug combo reawaken the immune system against resistant cancers?
Disease control Recruiting nowThis trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …
Phase 1/2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Experimental pill GS-1206 takes aim at Hard-to-Treat solid tumors
Disease control Recruiting nowThis study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New antibody drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for tough cancers: experimental drug IMGS-001 enters human trials
Disease control Recruiting nowThis early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…
Phase 1 • Sponsor: ImmunoGenesis • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new pill shrink advanced solid tumors?
Disease control Recruiting nowThis trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…
Phase 1/2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Which heat treatment shrinks thyroid nodules better?
Disease control Recruiting nowThis trial compares two minimally invasive procedures, radiofrequency ablation (RFA) and microwave ablation (MWA), for treating large benign thyroid nodules. Adults with a single nodule of at least 20 milliliters will be randomly assigned to one of the two heat-based treatments. …
Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with brain spread
Disease control Recruiting nowThis early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …
Phase 1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Belzutifan extension trial aims to extend lives in VHL and advanced cancer
Disease control Recruiting nowThis extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug SKB565 aims to fight advanced solid tumors
Disease control Recruiting nowThis study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…
Phase 1/2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a blister beetle extract banish common warts? phase 3 trial investigates
Disease control Recruiting nowThis Phase 3 trial tests YCANTH, a topical solution containing cantharidin (a substance from blister beetles), against a placebo for treating common warts. About 300 people aged 2 and older with at least one wart on their body (excluding certain areas) will receive either the act…
Phase 3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New pill shows promise for rare tumors in Mid-Stage trial
Disease control Recruiting nowThis phase 2 study tests belzutifan, a daily pill that blocks a protein called HIF-2α, in people with advanced rare cancers like pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumors, VHL disease-associated tumors, and certain other solid tumors. The goal is to see if …
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug VBC101 targets tough cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New pill targets HER2 cancers in promising trial
Disease control Recruiting nowThis Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…
Phase 2 • Sponsor: Bayer • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for tough cancers: experimental drug IPN01203 enters human trials
Disease control Recruiting nowThis study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…
Phase 1/2 • Sponsor: Ipsen • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New pill targets rare cancer gene in 30-Patient trial
Disease control Recruiting nowThis phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the…
Phase 2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can microwave ablation outperform radiofrequency for thyroid nodules?
Disease control Recruiting nowThis trial tests whether microwave ablation can shrink benign thyroid nodules more effectively than the standard radiofrequency ablation. Both methods use heat to destroy nodule tissue without surgery. The study enrolls adults with moderate-sized, mostly solid, benign nodules tha…
Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
BioNTech launches trial of BNT326 for advanced cancers
Disease control Recruiting nowThis study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug targets hard-to-treat cancers with missing MTAP gene
Disease control Recruiting nowThis early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…
Phase 1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
One spot, many warts: heat and peroxide may trigger a full clearance
Disease control Recruiting nowThis trial tests a two-part approach for viral warts: applying mild heat at 44°C to the largest wart and using a 3% hydrogen peroxide solution on all warts. The idea is that heating one lesion may rally the immune system to fight the virus elsewhere, while the peroxide works dire…
Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a platform trial match the right drug combo to each tumor?
Disease control Recruiting nowThis phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…
Phase 1/2 • Sponsor: QuantumLeap Healthcare Collaborative • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for advanced cancers? first human trial of DS5361b begins
Disease control Recruiting nowThis early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug NEOK001 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …
Phase 1 • Sponsor: NEOK Bio, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug aims to stop nosebleeds in rare blood vessel disorder
Disease control Recruiting nowThis study tests an experimental drug called ATV-1601 in people with moderate to severe HHT, a condition that causes frequent nosebleeds and anemia. The trial has two parts: first, participants receive either the drug or a placebo to check safety and effectiveness; then, all elig…
Phase 1/2 • Sponsor: Atavistik Bio, Inc • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can your Cancer's genes pick the right drug? TAPUR study aims to find out
Disease control Recruiting nowThe TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…
Phase 2 • Sponsor: American Society of Clinical Oncology • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug IMA402 targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.
Phase 1/2 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug targets two cancer proteins in advanced tumors
Disease control Recruiting nowThis trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug could protect children with cancer from chemo side effects
Disease control Recruiting nowThis study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.
Phase 2 • Sponsor: Spectrum Pharmaceuticals, Inc • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug IPN01195 enters human trials
Disease control Recruiting nowThis study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …
Phase 1/2 • Sponsor: Ipsen • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New shot could make cancer treatment easier for patients with advanced tumors
Disease control Recruiting nowThis study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Experimental CAR t therapy takes on solid tumors in first human trial
Disease control Recruiting nowThis early-phase trial is testing a new immunotherapy called LEU011 for people with advanced solid tumors that have not responded to other treatments. LEU011 uses the patient's own immune cells, modified to better recognize and attack tumor cells. The study aims to find a safe do…
Phase 1/2 • Sponsor: Leucid Bio • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
A pill that fights warts from the inside: trial puts immune-regulating capsule to the test
Disease control Recruiting nowThis trial tests whether a daily oral capsule called 2LVERU can clear common, flat, or plantar warts caused by HPV. Researchers compare the capsule against a placebo in 162 people aged 3 and older over 6 months. The main question is whether warts disappear completely by the end o…
Phase 4 • Sponsor: Labo'Life • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat kidney cancer
Disease control Recruiting nowThis early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug combo takes on tough tumors
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called CX-801, alone or with the immunotherapy Keytruda, in 121 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will…
Phase 1 • Sponsor: CytomX Therapeutics • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for advanced cancer: first human trial of FZ-AD004 begins
Disease control Recruiting nowThis study tests a new drug, FZ-AD004, for the first time in people with advanced solid tumors that have spread or cannot be removed. The goal is to find a safe dose and see if it can shrink tumors. About 121 adults aged 18 to 75 will take part.
Phase 1 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New chemo injection targets tumors directly in early trial
Disease control Recruiting nowThis early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…
Phase 1 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug combo trial hopes to tackle advanced cancers
Disease control Recruiting nowThis study is testing an experimental drug called LM-2417, given alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see early signs of tumor shrinkage. …
Phase 1/2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Cancer-Fighting virus injected into tumors shows promise in early trial
Disease control Recruiting nowThis early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…
Phase 1 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug BL-B01D1 shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BL-B01D1 in people with advanced stomach or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any side effects. About 96 adults aged 18 to 75 will take part, and r…
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug BL-B01D1 targets Hard-to-Treat solid tumors in early trial
Disease control Recruiting nowThis Phase II trial is testing a drug called BL-B01D1 in 76 adults with advanced urinary system or other solid tumors that have not responded to standard treatments. The study aims to find the best dose and see how well the drug shrinks tumors, while also monitoring safety and si…
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Bacteria engineered to starve tumors enters human trials
Disease control Recruiting nowThis early-phase trial is testing a modified salmonella bacteria, called SGN1, in 70 people with advanced solid tumors that have not responded to standard treatments. The bacteria are designed to grow inside tumors and release an enzyme that breaks down methionine, an amino acid …
Phase 1/2 • Sponsor: Guangzhou Sinogen Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Bacteria battle cancer: modified salmonella starves tumors in new trial
Disease control Recruiting nowThis study tests a modified salmonella bacteria (SGN1) injected directly into tumors. The bacteria are designed to grow inside tumors and cut off their food supply (an amino acid called methionine), causing the tumors to shrink. The trial involves about 70 adults with advanced so…
Phase 1/2 • Sponsor: Guangzhou Sinogen Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug ARC101 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called ARC101 in 70 people with advanced solid tumors that have a specific marker (Claudin 6). The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants must have ovarian, testicular, or ot…
Phase 1 • Sponsor: Third Arc Bio • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: experimental drug E303 enters human trials
Disease control Recruiting nowThis early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …
Phase 1 • Sponsor: Samsung Bioepis Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Virus therapy takes on tough cancers in early trial
Disease control Recruiting nowThis early-phase study is testing a modified virus called OTS-412, given alone or with hydroxyurea and the immunotherapy atezolizumab, in 27 adults with solid tumors that have stopped responding to standard treatments. The main goal is to check safety and side effects, while also…
Phase 1 • Sponsor: Bionoxx Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug ORB-021 enters early human testing for advanced cancers
Disease control Recruiting nowThis early-phase trial is testing whether a new drug called ORB-021 is safe and tolerable for people with advanced solid tumors who have no standard treatment options left. About 36 adults will receive the drug through an IV to find the best dose for future studies. The main goal…
Phase 1 • Sponsor: Orionis Biosciences Inc • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new drug tame tumors that resist standard therapy?
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called ONO-7429 in about 80 people with advanced or recurrent solid tumors that have not responded to or cannot tolerate standard treatments. The main goal is to find out whether the drug is safe and tolerable, and to determi…
Phase 1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New radiation approach aims to stop brain tumor regrowth
Disease control Recruiting nowThis pilot trial is testing a type of radiation called hypofractionated stereotactic radiosurgery for people who have had surgery for a grade II or recurrent grade I meningioma. The treatment delivers higher doses of radiation in fewer sessions, which may kill leftover tumor cell…
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug DS1025a takes on advanced solid tumors in first human trial
Disease control Recruiting nowThis trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Radioactive therapy targets rare tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests a radioactive drug called Lu-177-DOTATATE in 130 adults with rare adrenal or neck tumors that cannot be surgically removed. The drug is given four times over about 8 months, and researchers track how long the cancer stays under control. The goal is to see…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug targets root cause of rare overgrowth syndromes
Disease control Recruiting nowThis Phase 2 study tests an oral drug called RLY-2608 in adults and children with overgrowth conditions (like CLOVES or Klippel-Trenaunay syndrome) caused by PIK3CA gene mutations. The drug is designed to block the faulty protein driving abnormal tissue growth. The trial will enr…
Phase 2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Experimental cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…
Phase 1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Experimental injection targets tumors directly in new cancer trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…
Phase 1 • Sponsor: Vaxiion Therapeutics • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new drug shrink advanced solid tumors?
Disease control Recruiting nowThis trial is testing an investigational drug called SHR-A2102, given alone or with other anti-tumor therapies, in people with advanced solid tumors. The goal is to find a safe and effective dose and see how well it shrinks tumors. Participants must be adults with certain types o…
Phase 1/2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Proton beam therapy tested for brain tumors: could spare healthy tissue?
Disease control Recruiting nowThis study is testing proton radiation as a treatment for adults with benign or slow-growing brain tumors. Researchers want to see how well it controls tumor growth and how it affects quality of life and side effects. About 100 participants will receive proton radiation and be fo…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New cancer drug candidate SHR-4685 enters first human tests
Disease control Recruiting nowThis early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…
Phase 1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New injection could help kids with rare growths avoid major surgery
Disease control Recruiting nowThis study tests an injected medicine called TARA-002 for children aged 6 months to 18 years who have lymphatic malformations (fluid-filled cysts). The goal is to see if the injections can safely shrink or eliminate the cysts. Up to 38 children will receive up to 4 injections, ea…
Phase 2 • Sponsor: Protara Therapeutics • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New immune cell therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a drug duo outsmart resistant tumors?
Disease control Recruiting nowThis trial is testing whether two experimental oral drugs, APG-115 and APG-2575, can help people with neuroblastoma or other solid tumors that have returned or not responded to standard treatment. The study will first find the safest dose, then expand to see how well the drugs wo…
Phase 1/2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New injection YKYY031 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …
Phase 1 • Sponsor: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New daily pill hopes to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental daily pill called REC-1245 in people with advanced solid tumors or lymphomas that have not responded to or are not eligible for standard therapies. The main goals are to find a safe dose and check if the drug can shrink tumors. About 170 adults wi…
Phase 1/2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug LOXO-435 targets Hard-to-Treat bladder cancers
Disease control Recruiting nowThis early-stage trial is testing a new oral drug called LOXO-435, alone or with other cancer medicines, in people with advanced solid tumors that have a specific change in the FGFR3 gene. The study aims to find the right dose and check for safety and early signs of effectiveness…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a new injection tame advanced solid tumors?
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called HS-20117-2 in people with advanced solid tumors. The main goals are to understand how the drug behaves in the body, check its safety, and see how well people tolerate it. Participants receive the drug as a subcutaneous…
Phase 1 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a grid of radiation beams shrink tumors that resist standard treatment?
Disease control Recruiting nowThis trial is investigating whether spatially fractionated radiotherapy, a technique that delivers radiation in a grid-like pattern, can safely and effectively treat bulky (larger than 4 cm) or refractory solid tumors. The study will measure how many patients complete the treatme…
Phase 1/2 • Sponsor: Xu Zhi-yuan • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New Dual-Action antibody takes on advanced cancers
Disease control Recruiting nowThis study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth and immune evasion. The trial has two phases: fir…
Phase 1/2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for advanced cancer: APR-1051 enters first human trial
Disease control Recruiting nowThis early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…
Phase 1 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a Dual-Action antibody outsmart resistant tumors?
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called GIM-122 in adults with advanced solid tumors that have not responded to standard treatments, including PD-1/PD-L1 inhibitors. GIM-122 is a special antibody designed to fight cancer in two ways. The study aims to fin…
Phase 1/2 • Sponsor: Georgiamune Inc • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Could simple Over-the-Counter drugs supercharge cancer immunotherapy?
Disease control Recruiting nowThis study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…
Phase 2 • Sponsor: Val Adams • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill takes on advanced cancers in first human test
Disease control Recruiting nowThis early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…
Phase 1 • Sponsor: Groovy Medicine (Hangzhou) Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can sound waves replace the scalpel for breast tumors?
Disease control Recruiting nowThis trial tests a combined imaging and treatment method called HMIgFUS for breast tumors. The approach uses focused ultrasound waves to heat and destroy tumor tissue, while a special imaging technique monitors the process in real time by measuring tissue stiffness. The study inc…
Phase 1 • Sponsor: Columbia University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New master trial aims to speed up cancer treatments for kids
Disease control Recruiting nowThis trial tests several cancer drugs in children and young adults with solid tumors. It uses a master protocol to test different drug combinations more efficiently. About 105 participants will receive one of eight drugs, including ramucirumab, cyclophosphamide, and others. The g…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new pill help the immune system fight cancer?
Disease control Recruiting nowThis trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…
Phase 1/2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
Disease control Expanded accessThis study offers access to a radioactive therapy called 131I-MIBG for people with neuroblastoma or pheochromocytoma that has returned or stopped responding to standard treatments. The therapy is designed to seek out and deliver radiation directly to tumor cells. Researchers are …
Sponsor: Northwell Health • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can an mRNA therapy supercharge the immune system against cancer?
Disease control Recruiting nowThis trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…
Phase 1/2 • Sponsor: Strand Therapeutics Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…
Phase 1 • Sponsor: Exelixis • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Zinc-Based compound fight cancer?
Disease control Recruiting nowThis trial tests an experimental drug called KLS-1, a form of zinc aspartate enriched with a specific zinc isotope, in adults with certain solid tumors (like melanoma, prostate, or pancreatic cancer) or chronic lymphocytic leukemia (CLL). The goal is to find the safest and most e…
Phase 1/2 • Sponsor: Vector Vitale LLC • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a new immunotherapy combo shrink Hard-to-Treat tumors?
Disease control Recruiting nowThis early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…
Phase 1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Patient's own immune cells fight advanced cancer?
Disease control Recruiting nowThis trial investigates whether tumor-infiltrating lymphocytes (TILs) — immune cells taken from a patient's own tumor — can be expanded in the lab and infused back to attack cancer. It enrolls adults aged 18 to 75 with advanced solid tumors who have failed standard treatments. Th…
Early phase 1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New pill targets genetic weakness in tough cancers
Disease control Recruiting nowThis early-stage trial tests a new daily pill called TYRA-430 in 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the dr…
Phase 1 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Personalized maintenance therapy: a smarter way to treat advanced cancer?
Disease control Recruiting nowThis phase II trial is testing whether continuing targeted therapy or immunotherapy based on a tumor's molecular profile can benefit patients with advanced solid tumors that have stopped responding to prior treatment. After an initial treatment period, patients whose disease is s…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a new drug called ROSE12 help fight advanced solid tumors?
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called ROSE12, alone or combined with other anti-tumor agents, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to evaluate safety, determine the best dose, and look…
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a new pill shrink Hard-to-Treat tumors? a trial aims to find out
Disease control Recruiting nowThis phase 3 trial is testing an experimental drug called VC004 in people aged 12 and older with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see whether VC004 capsules can shrink tumors and control the disease. All participants receive th…
Phase 3 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New enzyme shot takes aim at Hard-to-Treat tumors
Disease control Recruiting nowThis trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…
Phase 1/2 • Sponsor: Onchilles Pharma Inc • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
A new care pathway aims to get cancer surgery patients home safer and faster
Disease control Recruiting nowThis large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…
Sponsor: Regional Specialist Hospital in Wroclaw • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
Disease control Recruiting nowThis trial is testing an experimental drug called AT-1965 in people with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and then seeing whether the drug can shrink tumors. About 100 participants will…
Phase 1/2 • Sponsor: Alyssum Therapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New pill could shrink abnormal vessels in rare childhood disorders
Disease control Recruiting nowThis Phase 3 trial tests an oral drug called KP-001 in 150 people aged 2 and older with venous malformations, lymphatic malformations, or KTS/CLOVES syndrome. Participants receive either KP-001 or a placebo for 24 weeks, then everyone gets the drug for another 28 weeks. The goal …
Phase 3 • Sponsor: Kaken Pharmaceutical • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New immune drug STK-012 takes on tough lung cancers
Disease control Recruiting nowThis study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …
Phase 1/2 • Sponsor: Synthekine • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can engineered red blood cells fight cancer? new trial launches
Disease control Recruiting nowThis early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…
Early phase 1 • Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Engineered virus targets Hard-to-Treat cancers from the inside
Disease control Recruiting nowThis study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…
Phase 2 • Sponsor: Tianjin First Central Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New trial matches cancer drugs to tumor DNA for advanced patients
Disease control Recruiting nowThis study tests targeted cancer drugs in people with advanced solid tumors that have not responded to standard treatments. Participants receive a drug chosen based on the genetic changes in their tumor. The goal is to see if the treatment can stop or shrink the cancer for at lea…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New targeted cancer drug STX-478 enters human trials
Disease control Recruiting nowThis study tests a new drug called STX-478 in people with advanced solid tumors that have a specific genetic change (PI3Kα mutation). The trial has two phases: first, it tests STX-478 alone to find safe doses; then, it combines STX-478 with other cancer drugs like fulvestrant or …
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could old drugs beat rare cancers? new trial aims to find out
Disease control Recruiting nowThe DETERMINE trial is testing whether drugs already approved for some cancers can help people with rare cancers or common cancers that have rare genetic mutations. It will enroll 825 adults, teenagers, and children whose cancers have specific DNA changes. The goal is to find new…
Phase 2/3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New cocktail of old drugs takes on advanced cancers
Disease control Recruiting nowThis Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…
Phase 2 • Sponsor: Sarcoma Oncology Research Center, LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with rare TP53 mutation
Disease control Recruiting nowThis study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …
Phase 1/2 • Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Cancer drug pelabresib gets Long-Term safety check in extension trial
Disease control Recruiting nowThis study looks at the long-term safety and benefits of the drug pelabresib in people with blood cancers, solid tumors, or advanced cancers. It includes up to 50 adults who were in earlier pelabresib studies and are still benefiting from the drug. Some participants who received …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Smart immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…
Phase 1/2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New heat therapy could replace surgery for Hormone-Fueled hypertension
Disease control Recruiting nowThis study compares two treatments for a condition called primary aldosteronism, where a small adrenal gland tumor causes high blood pressure. One treatment is laparoscopic surgery to remove the tumor; the other is radiofrequency ablation (RFA), which uses heat delivered through …
Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…
Phase 1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Promising combo targets Hard-to-Treat childhood cancers
Disease control Recruiting nowThis study is testing a combination of two drugs—a targeted radioactive drug (177Lu-DOTATATE) and a PARP inhibitor (olaparib)—in children and teens aged 3 to 18 with certain solid tumors that have come back or not responded to treatment. The goal is to see if the combination is s…
Phase 1/2 • Sponsor: Fundación de investigación HM • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New experimental drug SIM0613 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…
Phase 1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New biologic JLM019 enters human testing for advanced cancers
Disease control Recruiting nowThis early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …
Phase 1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo aims to shield heart while fighting tumors
Disease control Recruiting nowThis early-phase study tests a new drug called RC220 given with the chemotherapy doxorubicin in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if RC220 can protect the heart from doxorubicin's sid…
Phase 1 • Sponsor: Racura Oncology Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New particles aim to shrink fibroids without surgery
Disease control Recruiting nowThis study is testing Bearing nsPVA particles, used during a procedure called uterine artery embolization, to treat uterine fibroids in 100 women. The goal is to see if these particles safely block blood flow to fibroids, reducing symptoms like pain and heavy bleeding. Participan…
Sponsor: Merit Medical Systems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New study seeks safer dosing of cancer drug for patients with liver issues
Disease control Recruiting nowThis study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) works in people with moderate or severe liver problems. About 27 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to understand how the liver affects t…
Phase 1 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New study checks if kidney disease affects cancer drug safety
Disease control Recruiting nowThis early-stage study looks at how the body handles the cancer drug ASTX727 (decitabine and cedazuridine) in people with severe kidney problems compared to those with normal kidneys. It includes 18 adults with acute myeloid leukemia, myelodysplastic syndromes, or solid tumors. T…
Phase 1 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Chilling out to fight cancer: cold therapy meets immunotherapy in new trial
Disease control Recruiting nowThis early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Electric shock therapy may shrink blood vessel birthmarks
Disease control Recruiting nowThis study is testing a treatment called electrosclerotherapy for people with low-flow venous malformations (abnormal blood vessels present from birth). The goal is to shrink the malformation by at least 30% and reduce pain. About 65 participants will receive the treatment and be…
Sponsor: Istituto Ortopedico Rizzoli • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug cocktail aims to tackle Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called Risvutatug rezetecan (Ris-Rez) in people with advanced solid tumors that have spread or cannot be removed. The study will give Ris-Rez alone or combined with other cancer drugs like chemotherapy or immunotherapy. Researchers wan…
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Engineered T-Cells take on recurrent solid tumors in new trial
Disease control Recruiting nowThis study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells (T-cells) that are genetically modified in a lab to recognize and attack a protein called PRAME found on cancer cel…
Phase 1/2 • Sponsor: Immatics US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could a transplant drug shrink dangerous blood vessel tangles?
Disease control Recruiting nowThis study tests whether sirolimus, a drug used to prevent organ rejection, can shrink severe arteriovenous malformations (AVMs) and ease symptoms. About 50 people aged 2 and older with advanced AVMs will take the drug for a year. The goal is to see if the drug reduces AVM size b…
Phase 2 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
5-Drug cocktail takes on tough cancers in new trial
Disease control Recruiting nowThis study tests a mix of five oral drugs (hydroxychloroquine, metformin, sirolimus, dasatinib, and nelfinavir) in people with advanced solid tumors or prostate cancer that has come back. The goal is to find the safest dose and see if the combination can stop the cancer from grow…
Phase 1/2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New study aims to cut bleeding in fibroid surgery
Disease control Recruiting nowThis study tests if temporarily blocking the blood supply to the uterus and ovaries during minimally invasive fibroid surgery can reduce blood loss. About 120 women with large or numerous fibroids will be randomly assigned to receive the vessel-blocking technique or standard surg…
Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for advanced cancers: first human trial of ODM-212 begins
Disease control Recruiting nowThis study tests a new drug, ODM-212, in about 315 adults with advanced solid tumours that cannot be cured with current treatments. The trial has two parts: first finding a safe dose, then testing that dose in more people. The main goal is to check for side effects and see how th…
Phase 1/2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for rare vascular malformations: targeted drugs enter trial
Disease control Recruiting nowThis phase 2 trial is testing two targeted drugs—alpelisib and mirdametinib—in 50 people with slow-flow or fast-flow vascular malformations that haven't responded to standard treatments. The goal is to see if these drugs can improve each person's most bothersome symptom over 48 w…
Phase 2 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New antibody combo takes on advanced solid tumors
Disease control Recruiting nowThis study tests a new drug called DT-7012, alone or with another cancer drug (an immune checkpoint inhibitor), in 125 adults with advanced solid tumors that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors. It is an earl…
Phase 1/2 • Sponsor: Domain Therapeutics Australia Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for stubborn warts: extended treatment shows promise
Disease control Recruiting nowThis study follows people who already took part in earlier YCANTH wart studies. It tests whether up to 4 more treatments, applied every 21 days, can safely clear common warts. About 600 adults and children will be monitored for a year. The goal is to see if the medicine continues…
Phase 3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New Immune-Boosting drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called REGN10597, alone or with another drug (cemiplimab), in people with advanced solid tumors like melanoma and kidney cancer. The goal is to see if the treatment is safe and can shrink tumors. About 240 participants will receive the drug i…
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New program aims to cut risky drug mix-ups for kids on multiple medications
Disease control Recruiting nowThis study tests a program called Pediatric Medication Therapy Management (pMTM) for children with complex medical conditions who take five or more medications. The program involves a thorough review of all medicines, optimizing the regimen, and creating a clear medication plan. …
Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New gel could ease painful skin growths
Disease control Recruiting nowThis phase 2 trial tests a gel called PTX-022 (sirolimus) on people aged 6 and older with angiokeratomas, which are small, raised skin spots. The study will check if the gel is safe and helps improve the appearance of these spots. Fifteen participants will apply the gel and be mo…
Phase 2 • Sponsor: Palvella Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New radiation 'Lattice' method paired with immunotherapy shows promise for tough cancers
Disease control Recruiting nowThis phase 2 trial tests a new radiation technique called lattice radiation therapy (LRT) combined with immunotherapy in 30 people with advanced solid tumors that have not responded to standard treatments. LRT delivers high doses of radiation to small spots inside the tumor while…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug aims to reactivate Cancer-Fighting genes in solid tumors
Disease control Recruiting nowThis phase 2 trial is testing valemetostat, a daily pill, in 900 adults with advanced solid tumors that have specific gene changes (like SMARCB1 or ARID1A). The drug works by blocking EZH1/2 enzymes to reactivate genes that normally protect against cancer. The main goal is to see…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill could ease psoriatic arthritis pain in 12 weeks
Disease control Recruiting nowThis study tests an experimental oral drug called D-2570 in 222 adults with active psoriatic arthritis. Participants take the drug or a placebo daily for 12 weeks. The main goal is to see if D-2570 reduces joint tenderness and swelling by at least 20% compared to placebo.
Phase 2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill shows promise against childhood brain tumor
Disease control Recruiting nowThis study is testing a drug called Tovorafenib for children and young adults with craniopharyngioma, a rare, non-cancerous brain tumor that can cause serious health problems. The drug is taken by mouth and works by blocking a protein that helps the tumor grow. The trial aims to …
Phase 2 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests an experimental oral drug called NST-628 in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 230 partic…
Phase 1 • Sponsor: Nested Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Electric pulses zap thyroid lumps in new trial
Disease control Recruiting nowThis study tests a new device that uses electrical pulses to shrink benign (non-cancerous) thyroid nodules. About 100 adults with symptomatic nodules will receive the treatment and be followed to see if the nodule shrinks and symptoms improve. The goal is to offer a less invasive…
Sponsor: Pulse Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for rare cancers: immunotherapy drug targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…
Phase 2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New antibody PRL3-Zumab tested against advanced cancers
Disease control Recruiting nowThis study tests an experimental drug called PRL3-zumab in 52 adults with advanced solid tumors. The drug is given by IV every two weeks. Researchers want to see if it can slow cancer growth and how safe it is. Participants must have had no more than three prior treatments and be…
Phase 2/3 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug ATG-022 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called ATG-022 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Up to 156 participants will receive the drug every three…
Phase 1 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New CAR-T therapy aims to outsmart Hard-to-Treat solid cancers
Disease control Recruiting nowThis early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment using donor immune cells (CAR-NK cells) that are engineered to recognize and attack cancer. The treatment is personalized based on a tumor's unique markers. It is for adults with advanced solid tumors that have not responded to other therapies. Th…
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Off-the-Shelf immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing NK042, a ready-made natural killer cell therapy made from healthy donors, in 76 people with advanced solid tumors that have not responded to standard treatments. Participants first receive chemotherapy to prepare their immune system, then an infu…
Phase 1 • Sponsor: Shanghai NK Cell Technology Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental virus therapy takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …
Phase 1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New daily pill hopes to control advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…
Phase 1/2 • Sponsor: 858 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a plant extract reduce thyroid nodules? new study seeks answers
Disease control Recruiting nowThis study tests whether Prunella oral liquid, a herbal remedy, can safely shrink benign (non-cancerous) thyroid nodules. About 234 adults with solid nodules between 1 and 3 cm will take the liquid or a placebo for 9 months. Researchers will measure changes in nodule size and che…
Phase 4 • Sponsor: Xintian Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called INV-1120, either by itself or combined with the immunotherapy pembrolizumab (Keytruda), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses an…
Phase 1 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Common diabetes drug may shield kidneys from chemo damage
Disease control Recruiting nowThis study tests whether dapagliflozin, a drug used for diabetes, can prevent kidney damage caused by platinum-based chemotherapy in people with solid tumors. About 46 participants will receive either dapagliflozin or a placebo for a few days around their chemo session. Researche…
Phase 2 • Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New injection targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid canc…
Phase 1 • Sponsor: Ankyra Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Radiation boosts immunotherapy in Hard-to-Treat cancers?
Disease control Recruiting nowThis pilot study tests whether giving precise, high-dose radiation to all visible tumors (up to 10) can improve the effectiveness of immunotherapy in people with advanced solid tumors that have spread. About 28 adults with 3-10 metastases will receive radiation over 3 weeks while…
Phase 1 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Engineered immune cells take aim at childhood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells, which are genetically modified in the lab to recognize and attack cancer cells…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Engineered donor cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…
Phase 1/2 • Sponsor: Essen Biotech • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could early radiation prevent spine fractures in cancer patients?
Disease control Recruiting nowThis study tests whether giving radiation early to spine tumors that are not yet painful can prevent serious problems like fractures or spinal cord compression. About 74 adults with cancer that has spread to the spine will receive radiation before symptoms get worse. The goal is …
Phase 1/2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New shorter radiation therapy could tame brain tumors
Disease control Recruiting nowThis study tests a shorter course of high-dose proton radiation for people with non-cancerous brain tumors like meningiomas and schwannomas. The goal is to see if fewer treatments can still control tumor growth while reducing side effects and being more convenient. About 70 adult…
Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Immune cell therapy takes on Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment called EBNK-001, made from donor immune cells (natural killer cells), in people with advanced solid tumors that have not responded to standard therapies. Participants receive the cells after chemotherapy to prepare the body, along with low-dose in…
Phase 1/2 • Sponsor: Essen Biotech • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New immune therapy shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called RPTR-1-201 in 150 adults with advanced solid tumors that cannot be cured with standard treatments. The drug works by helping the body's immune cells attack cancer. The study aims to find the safest dose and see if the drug shrinks tu…
Phase 1/2 • Sponsor: Repertoire Immune Medicines • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New study seeks safer dosing of cancer drug for patients with liver issues
Disease control Recruiting nowThis early-stage study tests the drug pralatrexate in 24 adults with advanced cancer and varying levels of liver function. The goal is to see how the body processes the drug and to find the right dose for people with mild, moderate, or severe liver impairment. Participants receiv…
Phase 1 • Sponsor: Acrotech Biopharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Could a Once-Daily pill prevent deadly clots in cancer patients?
Disease control Recruiting nowThis study compares two different dosing schedules of the blood thinner apixaban (Eliquis) against no blood thinner in about 996 cancer patients at moderate risk for blood clots. Participants take either 2.5 mg twice daily, 5 mg once daily, or no anticoagulant for 6 months. The g…
Phase 3 • Sponsor: University of Vermont • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Pulse radiation may supercharge immunotherapy against cancer
Disease control Recruiting nowThis phase 2 trial is testing whether adding a special type of radiation called adaptive pulse radiotherapy to standard immunotherapy can help treat advanced solid tumors. The study will enroll 35 people who are already receiving or planning to receive immune checkpoint inhibitor…
Phase 2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New trial aims to spare young brains from radiation damage
Disease control Recruiting nowThis study is testing whether a newer type of radiation called proton therapy (IMPT) can treat children's brain tumors just as well as standard X-ray therapy (IMRT) but with fewer long-term side effects. About 94 children aged 6 to 16 with low-grade brain tumors will be randomly …
Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called TGI-5, given alone or with the immunotherapy nivolumab, in people with advanced solid tumors such as colorectal, liver, lung, and skin cancers. The study aims to find safe doses and check for side effects in about 194 participan…
Phase 1 • Sponsor: Hefei TG ImmunoPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could a cancer drug tame dangerous brain vessels?
Disease control Recruiting nowThis study tests whether the drug bevacizumab, given through a vein, can improve symptoms like headaches, seizures, and thinking problems in people with brain arteriovenous malformations (AVMs) that are too large or risky for surgery or radiation. About 54 adults with moderate to…
Phase 2/3 • Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental cell therapy takes on solid tumors in early trial
Disease control Recruiting nowThis early study tests a new cell therapy called GK01, made from a patient's own immune cells, for advanced solid tumors. Fifteen participants will receive GK01 alone or with chemotherapy after surgery. The main goal is to check safety, not yet to prove it works.
Phase 1 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Preventive radiation may stop bone metastases from causing fractures
Disease control Recruiting nowThis study tests whether giving radiotherapy early to high-risk bone metastases that are not yet causing symptoms can prevent future bone complications like fractures. About 120 adults with solid tumors and at least three bone metastases will be randomly assigned to either standa…
Sponsor: Cancer Research Antwerp • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New gel could zap away common warts in just weeks
Disease control Recruiting nowThis study tests a gel called YCANTH on common warts caused by HPV. About 300 people aged 2 and older with at least one wart will apply the gel or a fake version. The goal is to see if the gel can clear all warts by day 84.
Phase 3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New daily pill shows promise for tough cancers
Disease control Recruiting nowThis study tests a new tablet called ABP1011T in people with advanced solid tumors, including small cell lung cancer and others like esophageal or bladder cancer. Participants take one pill daily in 21-day cycles. The goal is to see if the drug can shrink tumors and how safe it i…
Phase 2 • Sponsor: Shanghai AB PharmaTech Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New liquid embolic agent could shrink dangerous brain malformations
Disease control Recruiting nowThis study tests a new liquid embolic agent to treat brain arteriovenous malformations (AVMs), which are tangles of abnormal blood vessels that can cause bleeding or stroke. About 116 adults aged 18 to 80 with certain types of AVMs will receive the treatment and be followed for o…
Sponsor: MicroPort NeuroTech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could a pill replace surgery for rare liver tumors?
Disease control Recruiting nowThis study tests a drug called baricitinib (a JAK1 inhibitor) to see if it can shrink large inflammatory liver adenomas (a rare, non-cancerous tumor) in 25 people. The goal is to reduce tumor size enough to avoid surgery. Participants will take the drug for a short time, and doct…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New Tumor-Injected drug shows promise in early cancer trial
Disease control Recruiting nowThis early-stage trial tests a new drug called ONM-501, which is injected directly into tumors, either alone or with the immunotherapy cemiplimab (Libtayo). The study includes 168 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The m…
Phase 1 • Sponsor: OncoNano Medicine, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
UK doctors trial tiny particle blockage to shrink thyroid lumps
Disease control Recruiting nowThis pilot study will test the safety of thyroid artery embolization (TAE) in 10 UK patients with benign thyroid nodules or goitre. TAE is a minimally invasive procedure that blocks blood flow to the thyroid gland using tiny particles, causing it to shrink. The goal is to see if …
Sponsor: Royal Berkshire NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New heat therapy could replace surgery for small tumors
Disease control Recruiting nowThis study is testing a procedure called EUS-RFA, which uses a thin needle guided by ultrasound to heat and destroy small tumors in the pancreas or adrenal glands. About 138 participants will receive this treatment as part of their standard care and be followed for up to 5 years.…
Sponsor: Herlev Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New combo aims to shrink penile cancer before surgery
Disease control Recruiting nowThis phase 2 trial tests whether giving pembrolizumab (Keytruda) plus chemotherapy (carboplatin and paclitaxel) before surgery can completely eliminate advanced penile cancer in the penis and lymph nodes. About 27 men with resectable, node-positive penile cancer will receive the …
Phase 2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New cancer drug combo shows early promise in tiny trial
Disease control Recruiting nowThis early study is testing a new drug called WTX212A, alone or with radiation, in 12 people with advanced solid tumors. The goal is to see if it shrinks tumors and is safe. It's a small first step to find out if this approach is worth studying further.
Phase 1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for kids with rare cancers: brigatinib trial opens
Disease control Recruiting nowThis study tests a drug called brigatinib in children and young adults (ages 1 to 25) with certain ALK-positive cancers, including anaplastic large cell lymphoma and inflammatory myofibroblastic tumors. The goal is to find the best dose and see how safe and effective the drug is.…
Phase 1/2 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for Hard-to-Treat cancers: ERAS-4001 enters human trials
Disease control Recruiting nowThis early-stage study tests a new drug called ERAS-4001 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and find the best dose, either alone or with other treatments. About 200 adults who have no good standard op…
Phase 1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Poop pills plus immunotherapy: new hope for stubborn cancers?
Disease control Recruiting nowThis study tests whether a fecal microbiota transplant (FMT) combined with the immunotherapy drug nivolumab can help people with advanced solid cancers that stopped responding to prior treatment. About 50 participants will receive the combination to see if it can shrink tumors. T…
Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a melanoma drug combo tame rare BRAF cancers?
Disease control Recruiting nowThis trial is testing two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific genetic change called BRAF V600 mutation. The goal is to see if the combination can shrink tumors or stop them from growing. About 3…
Phase 2/3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New radioactive nanoparticle targets tough tumors in early trial
Disease control Recruiting nowThis study tests a new radioactive drug called 177Lu-SN201 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target tumors using tiny particles. The main goals are to check safety, find the right dose, and see if it can s…
Phase 1/2 • Sponsor: Spago Nanomedical AB • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Can a common drug make fibroid surgery safer?
Disease control Recruiting nowThis study tests whether taking misoprostol before myomectomy (surgery to remove uterine fibroids) can reduce blood loss during the operation. 80 women aged 18-43 with symptomatic fibroids will receive either misoprostol or a placebo before surgery. The goal is to see if this sim…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New trial tests if proton beam therapy spares brain function better than standard X-Rays
Disease control Recruiting nowThis phase 3 trial compares proton beam therapy to standard photon radiotherapy in 156 adults with primary brain tumors. The goal is to see if proton therapy, which delivers less radiation to healthy brain tissue, improves functional survival—meaning living longer without tumor r…
Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Jun 26, 2026 18:34 UTC
-
New hope for VHL patients: belzutifan trial targets rare tumor disorder
Disease control Recruiting nowThis study tests the drug belzutifan in 100 people with von Hippel-Lindau (VHL) syndrome, a genetic condition that causes tumors in various organs. Researchers will track how well the drug shrinks tumors and how long it takes for the disease to progress, while also monitoring sid…
Phase 2 • Sponsor: José Claudio Casali da Rocha • Aim: Disease control
Last updated Jun 26, 2026 15:43 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis study tests A2B395, a donor-derived CAR T-cell therapy designed to target cancer cells while sparing healthy ones. It is for adults with advanced solid tumors like colorectal, lung, or breast cancer that have lost a specific immune marker. The trial has two phases: first to …
Phase 1/2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:35 UTC
-
Can AI learn to spot endometriosis and fibroids on ultrasound?
Diagnosis Recruiting nowResearchers at Semmelweis University are building and testing artificial intelligence algorithms that read standardized transvaginal ultrasound images. The study includes women aged 18 to 45 who have suspected endometriosis or adenomyosis, a confirmed uterine mass scheduled for s…
Sponsor: Semmelweis University • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
New 3D ultrasound aims to improve breast cancer diagnosis without radiation
Diagnosis Recruiting nowThis study is testing a new 3D automated ultrasound system called ATUSA to see how well it can image suspicious breast lesions. Up to 800 women with suspicious findings on standard imaging will get an ATUSA scan before their biopsy. The goal is to collect images and compare them …
Sponsor: iSono Health, Inc. • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Glowing dye could light up leftover cancer cells at surgery edges
Diagnosis Recruiting nowResearchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…
Sponsor: Erasmus Medical Center • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Blood test may unmask hidden genetic drivers of brain vessel malformations
Diagnosis Recruiting nowBrain arteriovenous malformations (bAVMs) are tangles of abnormal blood vessels that can rupture and cause bleeding in the brain. Researchers have found that these malformations often carry specific genetic mutations, but detecting them currently requires analyzing tissue removed…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
Targeted PET scan spots cancer protein, guiding treatment
Diagnosis Recruiting nowThis study tests a new PET scan that uses a special tracer to find a protein called CLDN18.2 on solid tumors. The goal is to see if this scan can help identify which patients might benefit from treatments that target this protein. About 15 adults with solid tumors will receive th…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Aug 28, 2026 00:00 UTC
-
Can a new PET tracer spot tumors more clearly?
Diagnosis Recruiting nowThis trial is testing two new PET imaging tracers, FAPI-RuiJ and FAPI-04, to see how well they detect, stage, and monitor various solid tumors. The study will compare the diagnostic accuracy of these tracers against standard methods in 200 adults with suspected or confirmed tumor…
Sponsor: Ruijin Hospital • Aim: Diagnosis
Last updated Aug 22, 2026 00:00 UTC
-
Can MRI outsmart blood tests for prostate cancer?
Diagnosis Recruiting nowThis study enrolls 950 men with suspected but undiagnosed prostate cancer who are scheduled for a biopsy. Researchers will compare the accuracy of prostate MRI against a panel of blood and urine biomarkers (PCA3, PSA, TMPRSS2:ERG) in detecting clinically significant prostate canc…
Sponsor: University of Michigan • Aim: Diagnosis
Last updated Aug 19, 2026 00:00 UTC
-
Can a new PET tracer reveal a key cancer target?
Diagnosis Recruiting nowThis trial is testing whether a new PET imaging agent can safely and effectively detect a protein called MMP14 on solid tumors. The study will involve about 30 adults with various solid tumors, such as melanoma, lung, or breast cancer. Each participant will receive the experiment…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
Diagnosis Recruiting nowThis study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Can a tracer that hunts unstable iron light up hidden tumors?
Diagnosis Recruiting nowThis phase 1 trial is testing whether a new imaging tracer called 18F-TRX can safely and effectively detect solid tumors using PET scans. The tracer targets unstable iron levels, which are often elevated in cancerous tissue. Adults with advanced solid tumors, including certain pr…
Phase 1 • Sponsor: Rahul Aggarwal • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
New scan could spot parathyroid tumors that old tests miss
Diagnosis Recruiting nowThis study tests whether a newer PET scan using 18F fluorocholine can find parathyroid adenomas that standard SPECT/CT scans miss. About 100 adults with high calcium and negative or unclear standard scans will receive the new scan. The goal is to see if the new method detects mor…
Phase 2/3 • Sponsor: Andrei Iagaru • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
Phone AI could spot eye disease in remote areas
Diagnosis Recruiting nowThis study tests a smartphone app that uses artificial intelligence to detect 16 different eye diseases from photos taken with the phone. The AI works entirely on the device, so no internet is needed. Researchers will compare its accuracy to eye doctors and see if non-medical use…
Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University • Aim: Diagnosis
Last updated Jun 27, 2026 13:05 UTC
-
Light may replace needle for breast cancer diagnosis
Diagnosis Recruiting nowThis study is testing whether special light-based scans (photoacoustic imaging and diffuse reflectance spectroscopy) can tell the difference between healthy, benign, and malignant breast tissue. Researchers will scan 90 women with known breast lumps and compare the scan results t…
Sponsor: Region Skane • Aim: Diagnosis
Last updated Jun 27, 2026 12:25 UTC
-
Smartphone screening could catch skin cancer sooner
Diagnosis Recruiting nowThis study is testing whether a telemedicine tool can help primary care doctors find skin cancer earlier. About 1,440 people with suspicious moles or lesions will have their skin checked remotely. The goal is to see if this approach can spot malignancies that might otherwise be m…
Sponsor: Institute of Health Information and Statistics of the Czech Republic • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
New scanner uses light and sound to spot breast tumors without needles
Diagnosis Recruiting nowThis study is testing a new device called the Photo-Acoustic Imager 3+ (PAM3+) that uses light and sound waves to create images of breast tissue. The goal is to see how well it can find both benign and malignant breast lesions in women referred to a breast clinic. About 180 women…
Phase 2 • Sponsor: Franciscus Gasthuis & Vlietland (Hospital) • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
Blood test may spot pancreatic cancer early, study hopes
Diagnosis Recruiting nowThis study aims to find blood-based biomarkers that can distinguish malignant pancreatic lesions from benign ones. Researchers will analyze blood samples from 100 adults with benign pancreatic conditions and compare them to existing data from patients with pancreatic cancer. The …
Sponsor: Centre Hospitalier Universitaire de Besancon • Aim: Diagnosis
Last updated Jun 27, 2026 11:01 UTC
-
Ultrasound may spot endometriosis without surgery
Diagnosis Recruiting nowThis study tests whether a specific ultrasound measurement can reliably detect superficial endometriosis on the uterosacral ligaments. Researchers will compare ultrasound findings with laparoscopic surgery results in 64 women undergoing gynecological surgery. If a clear cutoff th…
Sponsor: Casa di Cura Dott. Pederzoli • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
Headband device could spot hidden shunts without needles
Diagnosis Recruiting nowThis study tests a head-worn ultrasound device called SONAS that listens for bubble signals in the brain during a standard heart ultrasound. It aims to see if the device can accurately detect right-to-left shunts—abnormal connections between blood vessels—in adults with hereditar…
Sponsor: St. Antonius Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 09:06 UTC
-
New light device could spot skin cancer without cutting
Diagnosis Recruiting nowThis study is testing a device that shines a special light on skin growths to see if they are cancerous or harmless. The device looks for low oxygen levels, which can be a sign of cancer. Researchers will compare the device's results with standard biopsy results in 125 adults who…
Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
Blood test score could spot hidden Hormone-Making tumors
Diagnosis Recruiting nowThis study aims to create a new diagnostic score to better identify adrenal adenomas that produce moderate amounts of cortisol, a condition called MACS. Researchers will measure 19 steroid hormones in the blood and combine them with simple clinical factors like BMI, blood sugar, …
Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
New brain scan could spot tumors missed by standard MRI
Diagnosis Recruiting nowThis study tests whether a special PET/MRI scan using a radioactive tracer called Ga68-DOTATATE can better detect certain brain tumors (like meningioma) and tell them apart from changes caused by past treatments. About 200 adults with these tumors will get the scan alongside stan…
Phase 4 • Sponsor: Weill Medical College of Cornell University • Aim: Diagnosis
Last updated Jun 27, 2026 07:59 UTC
-
New shot could stop deadly clots in cancer patients
Prevention Recruiting nowThis phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Prevention
Last updated Sep 17, 2026 00:00 UTC
-
Broccoli compound put to the test against melanoma
Prevention Recruiting nowResearchers are testing whether sulforaphane, a substance found in broccoli and other cruciferous vegetables, can prevent melanoma in people who have multiple atypical moles and a prior history of melanoma. Participants take sulforaphane or a placebo by mouth. The trial measures …
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Prevention
Last updated Sep 17, 2026 00:00 UTC
-
Can a new drug shield nerves from Chemotherapy's side effects?
Prevention Recruiting nowThis phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…
Phase 2 • Sponsor: Sironax USA, Inc. • Aim: Prevention
Last updated Sep 03, 2026 00:00 UTC
-
Can a herbal oil shield cancer patients from chemo nerve pain?
Prevention Recruiting nowThis study tests whether a topical oil made from aconite can prevent or reduce nerve damage (polyneuropathy) caused by chemotherapy in cancer patients. About 350 adults with solid tumors receiving taxane or platinum chemotherapy will apply the oil or a placebo to their skin twice…
Phase 3 • Sponsor: WALA Heilmittel GmbH • Aim: Prevention
Last updated Aug 27, 2026 00:00 UTC
-
Can a simple gel shield fertility after fibroid surgery?
Prevention Recruiting nowThis trial tests whether placing a special gel inside the uterus after fibroid removal surgery can prevent the formation of scar tissue (adhesions) that may harm fertility. Women aged 18 to 45 who are scheduled for laparoscopic or abdominal myomectomy and have no pre-existing ute…
Sponsor: University Hospital, Ghent • Aim: Prevention
Last updated Aug 22, 2026 00:00 UTC
-
Green tea and vitamin D3 may stop fibroids returning after surgery
Prevention Recruiting nowThis study tests whether taking green tea extract (EGCG) and vitamin D3 daily can prevent uterine fibroids from growing back after surgical removal. About 240 women who have had fibroid surgery will receive either the supplements or a placebo. The goal is to see if this simple co…
Phase 2 • Sponsor: Sheikh Shakhbout Medical City • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Shingles vaccine put to the test in frail patients
Prevention Recruiting nowThis study looks at how well the shingles vaccine works in people with weakened immune systems, such as those with cancer or autoimmune diseases. Researchers will measure immune responses and track side effects in 300 adults. The goal is to see if the vaccine can effectively prev…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Prevention
Last updated Jun 27, 2026 09:11 UTC
-
Zapping thyroid nodules: a Needle-Free alternative to surgery?
Symptom relief Recruiting nowThis study tracks 50 people who choose radiofrequency ablation (RFA) for benign thyroid nodules or low-risk papillary thyroid cancer instead of surgery. Researchers will monitor long-term outcomes and quality of life using questionnaires. The goal is to see if RFA is a good alter…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New 'Lattice' radiation aims to zap tumor pain better than standard therapy
Symptom relief Recruiting nowThis phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …
Phase 3 • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New hope for cancer patients suffering from severe diarrhea and colitis from immunotherapy
Symptom relief Recruiting nowThis study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Lower back nerve block tested to cut pain after fibroid surgery
Symptom relief Recruiting nowResearchers are testing whether a quadratus lumborum nerve block reduces pain after laparoscopic myomectomy, a surgery to remove uterine fibroids while keeping the uterus. The block is a temporary anesthetic injection into a lower back muscle. In this double-blind, randomized tri…
Phase 4 • Sponsor: Joseph Findley MD • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Virtual reality goggles ease pain for kids with cancer
Symptom relief Recruiting nowThis study tests whether using a virtual reality helmet during painful medical procedures (like needle sticks or bone marrow tests) can reduce pain in children with cancer. About 74 children aged 6 to 18 will be split into two groups: one gets standard care plus the VR helmet, th…
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Magic mushroom therapy targets Cancer-Related depression
Symptom relief Recruiting nowThis phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can a Nerve-Blocking injection prevent salivary complications after parotid surgery?
Symptom relief Recruiting nowAfter surgery to remove a benign parotid tumor, some people develop salivary fistulas or sialoceles, which are collections of saliva that can leak or cause swelling. This pilot study tests whether injecting a long-acting local anesthetic called bupivacaine, combined with a steroi…
Early phase 1 • Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Fish or puppets: which distraction works best for needle-phobic kids?
Symptom relief Recruiting nowThis trial tests whether two simple distractions — watching a betta fish or playing with a hand puppet — can lower pain, fear, and anxiety in children aged 5 to 7 during a blood draw. One group will use the fish, another the puppet, and a third will receive standard care. Researc…
Phase 1 • Sponsor: Igdir University • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can an antidepressant calm Chemotherapy's nerve pain?
Symptom relief Recruiting nowThis trial tests whether duloxetine, a drug commonly used for depression, can reduce the painful nerve damage that some cancer patients experience after receiving taxane chemotherapy. The study enrolls adults with solid tumors who have at least moderate pain from this side effect…
Phase 2 • Sponsor: Yan Yang, MD, Ph.D • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
New radiation approach aims to shield memory during brain tumor treatment
Symptom relief Recruiting nowThis Phase 2 trial tests a new type of radiation therapy designed to avoid key brain areas involved in memory and thinking. Sixty adults with 1 to 3 small brain metastases will receive cognitive-sparing stereotactic radiosurgery. The main goal is to see if this approach better pr…
Phase 2 • Sponsor: Jona Hattangadi-Gluth • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
New therapy aims to ease spiritual distress in latino cancer patients
Symptom relief Recruiting nowThis study adapts a counseling program called Meaning Centered Psychotherapy for Latinos with advanced cancer. The goal is to improve spiritual well-being and quality of life. Researchers will enroll 190 Latino adults with stage III or IV solid tumors to test the program's feasib…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Cactus extract could zap cancer pain in new trial
Symptom relief Recruiting nowThis early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…
Phase 1 • Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Heat therapy as a palliative aid: does raising body temperature ease advanced cancer symptoms?
Symptom relief Recruiting nowThis study looks at whether a noninvasive treatment called whole-body infrared hyperthermia can help people with advanced solid tumors feel better. The therapy uses infrared energy to raise body temperature in a controlled way, and researchers will track changes in pain, fatigue,…
Sponsor: Zhejiang Hospital • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
A 45-minute chat could change how advanced cancer patients face tough decisions
Symptom relief Recruiting nowResearchers at Singapore General Hospital are testing whether a one-on-one coaching session, called CONCORD, helps patients with advanced cancer prepare for serious illness conversations with their doctors. The session, led by a trained lay coach, covers topics like understanding…
Sponsor: Singapore General Hospital • Aim: Symptom relief
Last updated Aug 29, 2026 00:00 UTC
-
Heat therapy may shrink thyroid lumps without surgery
Symptom relief Recruiting nowThis study looks at whether radiofrequency ablation (RFA) can safely reduce symptoms and improve quality of life in adults with benign thyroid nodules. Fifty participants will undergo the procedure and be followed for one year. The goal is to see if this minimally invasive heat t…
Sponsor: University Hospital, Ghent • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC
-
Phone coaching helps cancer patients have tough End-of-Life conversations
Symptom relief Recruiting nowThis study tests whether a telephone coaching program called Talking About Cancer (TAC) helps people with advanced cancer and their support person engage in advance care planning, such as having end-of-life conversations and completing advance directives. About 80 patients and th…
Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Aug 27, 2026 00:00 UTC
-
Timing your meals might ease cancer treatment side effects
Symptom relief Recruiting nowThis study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…
Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Aug 27, 2026 00:00 UTC
-
A good Night's sleep: could a simple program ease Cancer's toll on rest?
Symptom relief Recruiting nowThis study explores whether a brief behavioral program can help cancer patients and their sleep partners get better rest. The program teaches techniques like limiting time in bed and going to bed only when sleepy, aiming to improve sleep efficiency. Participants, who are couples …
Sponsor: University of Miami • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Can heat melt away lipomas without a scalpel?
Symptom relief Recruiting nowThis trial tests whether radiofrequency ablation (RFA) can safely and effectively treat superficial lipomas—benign fatty lumps under the skin—without leaving a scar. Instead of cutting out the lipoma, a thin needle delivers heat to melt it, guided by ultrasound. The study will me…
Sponsor: Columbia University • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Mushroom extract put to the test for advanced cancer Well-Being
Symptom relief Recruiting nowThis trial tests whether Yunzhi essence, a mushroom extract from Coriolus versicolor, can improve quality of life for people with advanced cancer. Participants take either the extract or a placebo for six months, while researchers measure changes in well-being, survival, and immu…
Phase 2 • Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
A simple diet and muscle relaxant may sharpen views in scarless hysterectomy
Symptom relief Recruiting nowThis trial tests whether a three-day low-residue diet and deeper muscle relaxation, alone or together, can improve the surgical view during vNOTES hysterectomy (a scarless procedure through the vagina). The study involves 160 women having hysterectomy for non-cancer conditions. R…
Sponsor: Fatih Sultan Mehmet Training and Research Hospital • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Could a wakefulness drug beat cancer fatigue? new trial aims to find out.
Symptom relief Recruiting nowThis study tests whether modafinil, a drug that promotes wakefulness, can reduce severe fatigue and thinking problems in people with advanced cancer. About 40 adults with stage III or IV cancer will receive either modafinil or a placebo for a short time. The goal is to see if the…
Phase 1/2 • Sponsor: Ottawa Hospital Research Institute • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
Can a breast cancer drug shrink fibroids? new trial aims to find out
Symptom relief Recruiting nowThis study tests whether the drug letrozole can improve symptoms and shrink fibroids in women with uterine fibroids. 140 participants will receive either letrozole or a placebo daily for 12 weeks. The main goal is to see if letrozole reduces symptom severity and improves quality …
Phase 4 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jul 24, 2026 00:00 UTC
-
Could a homeopathic remedy ease cancer treatment fatigue?
Symptom relief Recruiting nowThis study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…
Early phase 1 • Sponsor: Beaura for Para Pharmaceutical Products Trading LLC • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Could a nurse-led online therapy beat severe fatigue in advanced cancer?
Symptom relief Recruiting nowThis trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Squeeze away chemo pain: gloves and boots may stop nerve damage
Symptom relief Recruiting nowThis study tests special gloves and boots that gently squeeze the hands and feet during chemotherapy. The pressure may reduce how much chemo reaches the nerves, possibly preventing pain and numbness. About 142 adults with cancer will try the devices to see if they help avoid nerv…
Sponsor: Luminate Medical, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Simple injection may ease pain after hysterectomy surgery
Symptom relief Recruiting nowThis study tests whether injecting the local anesthetic bupivacaine into the small surgical cuts and the vaginal cuff at the end of a laparoscopic hysterectomy can lower postoperative pain. 120 women having the surgery for non-cancer reasons will be randomly assigned to receive t…
Sponsor: Serkan Kumbasar • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Card game aims to ease tough End-of-Life talks for cancer patients
Symptom relief Recruiting nowThis study tests whether a simple card game, the Go Wish Game, can help people with advanced blood cancers or solid tumors discuss their end-of-life priorities with doctors. About 75 patients will use the cards to sort what matters most to them, then complete an advance care plan…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Diabetes drug metformin tested to boost brain recovery in young cancer survivors
Symptom relief Recruiting nowThis Phase 3 trial tests whether metformin, a widely used diabetes drug, can improve memory and thinking in children and teens who have finished treatment for a brain tumor. About 140 participants aged 7 to 21 will take metformin or a placebo for 16 weeks. Researchers will measur…
Phase 3 • Sponsor: Donald Mabbott • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
New day hospital aims to ease transition for young cancer survivors
Symptom relief Recruiting nowThis study looks at whether a one-day hospital visit that includes medical, psychological, and social support can help teens and young adults (ages 15-25) feel better after finishing cancer treatment. About 214 participants who have completed treatment for a solid tumor or lympho…
Sponsor: Centre Leon Berard • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Hypnosis may calm cancer patients during radiation
Symptom relief Recruiting nowThis study looks at whether medical hypnosis can help reduce anxiety in people with solid tumors who are getting radiation therapy. About 45 moderately to very anxious patients will either listen to relaxing music alone or combine it with hypnosis during their sessions. The goal …
Phase 2 • Sponsor: Institut Claudius Regaud • Aim: Symptom relief
Last updated Jun 27, 2026 12:10 UTC
-
Robot buddies let kids with cancer attend class from hospital bed
Symptom relief Recruiting nowThis study tests whether telepresence robots can help children aged 5-17 with cancer attend school remotely when they can't be there in person. The robots let kids see, hear, and talk in class from their hospital or home. Researchers will track school attendance, social well-bein…
Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Nurse chats could ease cancer kids' suffering
Symptom relief Recruiting nowThis study tests whether specially trained nurses can help children with cancer and their families by starting conversations about palliative care early. About 120 children recently diagnosed with cancer will be randomly assigned to either receive these nurse-led talks or standar…
Sponsor: Children's Hospital of Fudan University • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Prehab before cancer surgery may boost recovery
Symptom relief Recruiting nowThis study tests whether a program of targeted exercise and psychological support before cancer treatment (called prehabilitation) can help patients with solid tumors recover better physically and emotionally. Researchers will compare this program to standard care in 125 adults w…
Sponsor: Priv.-Doz. Dr. med. Philipp Lenz • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Can a simple survey speed up care for advanced cancer patients?
Symptom relief Recruiting nowThis study tests whether electronic surveys can help people with advanced cancer report their symptoms and care needs, so their doctors can connect them to palliative (supportive) care services sooner. About 90 adults with incurable solid tumors will participate. The goal is to s…
Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Can a cream stop cancer Treatment's ugly side effect?
Symptom relief Recruiting nowThis study tests whether a cream containing tretinoin (a form of vitamin A) can prevent or reduce the acne-like rash that often occurs in patients taking certain cancer drugs. About 25 adults with advanced solid tumors will apply the cream to one side of their face and a placebo …
Phase 2 • Sponsor: University of Utah • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
Spinal shot vs IV drip: which helps you recover faster from robotic surgery?
Symptom relief Recruiting nowThis Phase 3 trial tests whether a single spinal injection of morphine and bupivacaine before robotic kidney or ureter surgery leads to better recovery than an intravenous lidocaine drip during surgery. About 220 adults scheduled for robotic upper urinary tract surgery will be ra…
Phase 3 • Sponsor: Hans Bahlmann • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Could a common supplement supercharge cancer immunotherapy?
Symptom relief Recruiting nowThis study tests whether urolithin A, a dietary supplement, can improve the immune system's response to standard immunotherapy drugs in people with newly diagnosed solid tumors like lung cancer or melanoma. 45 participants will be randomly assigned to receive either urolithin A o…
Sponsor: Goethe University • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Virtual workshops aim to help young cancer patients take control
Symptom relief Recruiting nowThis study tests whether remote health education workshops are feasible for adolescents and young adults with cancer. Participants will attend three online sessions designed to help them manage their disease and treatment. The goal is to see if patients stick with the program and…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Exercise may improve sleep for children battling blood cancer
Symptom relief Recruiting nowThis study looks at whether doing adapted physical activity every day can improve sleep quality in children aged 5 to 16 who are being treated for blood cancer. About 30 children will take part, with some exercising daily and others just once over four days. Parents will track sl…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
New study checks cancer Drug's effect on common medications
Knowledge-focused Recruiting nowThis study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Gene therapy survivors monitored for years in massive safety study
Knowledge-focused Recruiting nowThis study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…
Phase 2/3 • Sponsor: Celgene • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study checks how liver issues affect cancer drug pelabresib
Knowledge-focused Recruiting nowThis early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New trial uses DNA tests to match cancer patients to targeted drug cocktails
Knowledge-focused Recruiting nowThis large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists dig into DNA of moles to uncover hidden mutations
Knowledge-focused Recruiting nowThis study collects moles and blood samples from 50 adults to analyze the genetic mutations that cause moles to form. Researchers will compare DNA from mole tissue with normal DNA from blood to find specific changes. No treatments or interventions are given—the goal is purely to …
Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can fixing abnormal brain vessels help the brain clear its waste?
Knowledge-focused Recruiting nowResearchers are studying whether abnormal connections between arteries and veins in the brain's covering, called intracranial dural arteriovenous fistulae, affect the brain's waste-clearance system, known as the glymphatic system. About 20 adults who are already scheduled for sta…
Sponsor: Hospital Universitari Vall d'Hebron Research Institute • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Rare cancer syndrome under the microscope: what families need to know
Knowledge-focused Recruiting nowThis study follows people with a rare genetic condition called DICER1 syndrome, which raises the risk of certain childhood cancers like pleuropulmonary blastoma. Researchers will collect medical histories, genetic samples, and tissue from up to 1,500 participants and their relati…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists hunt for better ways to spot hidden adrenal tumors
Knowledge-focused Recruiting nowThis study aims to improve how doctors find and understand pheochromocytomas and paragangliomas, rare tumors that can cause dangerous high blood pressure. Researchers will use advanced imaging scans and genetic testing in up to 3,000 participants to learn more about these tumors.…
Phase 1 • Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists hunt for gene behind rare kidney cancer syndrome
Knowledge-focused Recruiting nowThis study aims to uncover the genetic causes of hereditary leiomyomatosis renal cell cancer (HLRCC), a condition that can lead to painful skin bumps, uterine fibroids, and kidney tumors. Researchers will study people with known or suspected HLRCC and their family members to iden…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Joint tissue study aims to personalize rare disease treatment
Knowledge-focused Recruiting nowThis study looks at whether analyzing synovial tissue can help doctors better manage pigmented villonodular synovitis (PVNS), a rare joint disease that causes pain and joint damage. Researchers will collect tissue samples from 30 patients through biopsy or surgery to assess quali…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Could your genes raise your melanoma risk? new study seeks answers
Knowledge-focused Recruiting nowThis study aims to understand how genetics and environmental factors contribute to melanoma, a serious skin cancer. Researchers will enroll up to 3,000 people with a personal or family history of melanoma or related conditions. Participants will fill out questionnaires, provide b…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Scientists launch global effort to unravel mysteries of rare lymphatic diseases
Knowledge-focused Recruiting nowThis study is creating a registry of up to 1,000 people with rare lymphatic system disorders. Researchers will collect information from medical records and yearly surveys to understand how these diseases progress, what treatments are used, and how they affect quality of life. The…
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
What do you risk for a chance at remission? cell therapy survey asks
Knowledge-focused Recruiting nowCell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…
Sponsor: Zhejiang University • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Scientists gather tumor samples to unlock new cancer treatments
Knowledge-focused Recruiting nowThis study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Cancer data pooling study aims to connect the dots across trials
Knowledge-focused Recruiting nowThis study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Scientists hunt for genetic clues behind childhood pituitary tumors
Knowledge-focused Recruiting nowThis study aims to uncover the genetic causes of pituitary and hypothalamic tumors in children. Researchers will collect blood and tumor samples from up to 2,000 participants to analyze DNA and look for inherited patterns. The study also trains doctors and tests new MRI technique…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Blood biomarkers may predict cancer treatment side effects
Knowledge-focused Recruiting nowThis pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or c…
Sponsor: University Hospitals Coventry and Warwickshire NHS Trust • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
New ultrasound probe and AI aim to sharpen thyroid nodule detection
Knowledge-focused Recruiting nowThis pilot study will test a new ultrasound probe and machine learning software to see if they can better visualize thyroid nodules compared to standard ultrasound. About 30 adults with known benign thyroid nodules will receive both types of scans. The goal is to improve detectio…
Sponsor: Sound Blade Medical Inc. • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
New imaging registry aims to sharpen cancer treatment precision
Knowledge-focused Recruiting nowThis study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …
Sponsor: Mark C Burgmans, MD PhD • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Study explores how medical info delivery shapes cancer care decisions
Knowledge-focused Recruiting nowThis study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Major study launches to unravel risks of birthmarks
Knowledge-focused Recruiting nowThis study follows 819 children under 2 years old who have medium to giant congenital nevi (pigmented birthmarks). Researchers will track neurological development, melanoma risk, and quality of life over time. The goal is to create better monitoring and treatment guidelines for t…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Scientists launch Long-Term study to unravel mysterious immune condition
Knowledge-focused Recruiting nowThis study follows 950 people with idiopathic CD4+ lymphocytopenia (ICL), a rare condition where low CD4+ white blood cells raise infection risk. Researchers will track participants for up to 10 years, collecting medical history, blood samples, and infection data. The goal is to …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Scientists hunt for genetic clues in bladder cancer samples
Knowledge-focused Recruiting nowThis study collects blood, urine, saliva, and tumor tissue from 500 adults with urothelial cancer (bladder, ureter, or urethra) and healthy volunteers. Researchers will analyze the samples to find genetic differences between normal and cancer cells. The goal is to better understa…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Global registry to track brain bleed surgery outcomes
Knowledge-focused Recruiting nowThis observational study will follow 2,500 people who had a brain hemorrhage and received minimally invasive surgery. Researchers want to see how well patients recover in real-world settings. The study does not test a new drug or procedure, but gathers data to improve future care…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Yale launches massive blood repository to unlock cancer secrets
Knowledge-focused Recruiting nowThis study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Massive childhood cancer registry launches to unlock better treatments
Knowledge-focused Recruiting nowThis study is a large registry that collects health information and leftover tumor or blood samples from up to 75,000 children and young adults with cancer. The goal is to track outcomes and gather data to help doctors find better ways to treat and care for these patients over ti…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Scientists track families to unlock secrets of inherited kidney cancer
Knowledge-focused Recruiting nowThis study follows families with a history of inherited kidney cancer to learn more about the disease's genetic causes and how it progresses. Researchers will collect blood, tissue, and urine samples from affected individuals and their relatives. The goal is to identify new genes…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Can we spot cancer before it starts? a massive study aims to find out
Knowledge-focused Recruiting nowThis study is building a large collection of blood, saliva, urine, stool, and tissue samples from people who are at increased risk of cancer, including those with genetic predispositions, survivors of childhood or adult cancer, or those with precancerous conditions. The goal is t…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Can a new questionnaire give patients a stronger voice in vascular malformation care?
Knowledge-focused Recruiting nowThis study aims to develop a standardized questionnaire that lets patients with venous malformations report their own symptoms and treatment outcomes. Venous malformations are abnormal veins that can cause pain, swelling, and emotional distress, and current assessments may miss w…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can a nudge in your chart unlock Life-Saving genetic clues?
Knowledge-focused Recruiting nowThis study tests whether simple reminders—called nudges—sent to doctors and patients can increase the use of genetic testing for people with certain conditions like Parkinson's disease, ALS, or heart problems. The trial will compare different ways of prompting genetic testing, su…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Tumor DNA mapping may unlock personalized cancer therapies
Knowledge-focused Recruiting nowThis study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…
Sponsor: Ulrik Lassen • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can modern Radiotherapy's late effects be predicted?
Knowledge-focused Recruiting nowThis study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Reading Cancer's genetic playbook: a quest to match patients to the right experimental therapy
Knowledge-focused Recruiting nowThis observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…
Sponsor: Institute of Cancer Research, United Kingdom • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
Knowledge-focused Recruiting nowThis trial asks whether five advanced AI models can match the treatment recommendations of expert tumor boards for cancer patients. Using 100 standardized synthetic cases across breast, lung, urological, digestive, and gynecological cancers, each AI and two independent tumor boar…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
AI heart test may spot hidden danger in older cancer surgery patients
Knowledge-focused Recruiting nowThis study will enroll 200 adults aged 60 or older who are scheduled for major surgery for urologic cancer. Researchers want to see if an artificial intelligence analysis of a standard heart test (ECG) taken before surgery can predict whether a patient will suffer heart injury or…
Sponsor: Korea University Anam Hospital • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Massive HHT registry aims to unlock secrets of rare bleeding disorder
Knowledge-focused Recruiting nowThis study creates a large registry of people diagnosed with hereditary hemorrhagic telangiectasia (HHT), a condition causing abnormal blood vessels and bleeding. Researchers will collect medical records and annual health updates for up to 10 years to understand how the disease c…
Sponsor: Cure HHT • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Tiny study peers inside brain after AVM surgery
Knowledge-focused Recruiting nowThis study will follow 10 adults with unruptured brain arteriovenous malformations (AVMs) who are scheduled for surgery. Researchers will use special brain scans to measure blood flow and energy use in different brain regions before and six months after the operation. The goal is…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
New approach aims to make repeat radiation safer for cancer patients
Knowledge-focused Recruiting nowThis study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…
Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a simple blood test predict leukemia risk after cancer therapy?
Knowledge-focused Recruiting nowThis study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can your mood impact pancreatic cancer survival?
Knowledge-focused Recruiting nowThis study looks at how ongoing stress, anxiety, and poor sleep might affect the course of pancreatic cancer. Researchers will ask 320 participants to fill out simple questionnaires about their mental well-being and will also measure stress markers in leftover blood samples. The …
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Gene-Guided cancer therapy: a new hope for advanced tumors?
Knowledge-focused Recruiting nowThis study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…
Sponsor: Seoul National University Bundang Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Hunt for hidden cancer genes: families needed to unlock hereditary secrets
Knowledge-focused Recruiting nowThis study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
770 cancer patients join study to unlock immunotherapy secrets
Knowledge-focused Recruiting nowThis study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Leftover surgery tissue could unlock secrets of hardening arteries and bones
Knowledge-focused Recruiting nowThis study uses leftover tissue from heart and orthopedic surgeries to learn more about how calcification (hardening) happens in bones and blood vessels. Researchers will grow cells from these tissues in the lab to study the process. The goal is to better understand the disease, …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists probe immune resistance in tumors to outsmart cancer
Knowledge-focused Recruiting nowThis study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
500 cancer patients join quest to unlock precision medicine secrets
Knowledge-focused Recruiting nowThis study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Blood biopsy study aims to improve cancer detection and monitoring
Knowledge-focused Recruiting nowThis study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Massive 15-year study launched to crack the code on rare brain-spine vessel disease
Knowledge-focused Recruiting nowThis study is a large registry that will collect data from over 10,000 people in China diagnosed with a rare condition where abnormal connections form between arteries and veins in the brain or spine. Researchers will track how common the disease is, what treatments are used, and…
Sponsor: Xuanwu Hospital, Beijing • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Gut bacteria linked to cancer survivor symptoms?
Knowledge-focused Recruiting nowThis study follows 600 childhood cancer survivors aged 8-18 to understand why symptoms like fatigue, pain, and depression often occur together. Researchers will use questionnaires and stool samples to see if gut bacteria and their byproducts play a role. The goal is to find bette…
Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
10,000 cancer patients join ontario Gene-Mapping effort to personalize care
Knowledge-focused Recruiting nowThis study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Brain surgery aftermath: new study tracks fluid leak risks
Knowledge-focused Recruiting nowThis study watches 200 adults having brain tumor surgery to see how often cerebrospinal fluid leaks happen and what makes them more likely. The goal is to find ways to prevent leaks and help people recover faster. No new treatment is being tested—just careful observation.
Sponsor: Medical University of Warsaw • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Stitch showdown: which scalp closure heals best after brain tumor surgery?
Knowledge-focused Recruiting nowThis study compares two common methods of closing the skin after brain tumor surgery: a continuous stitch under the skin using absorbable thread versus separate stitches through the skin using non-absorbable thread. Researchers want to see which method leads to fewer wound proble…
Sponsor: Medical University of Warsaw • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Personalized cancer care: DNA profiling guides patients to best trials
Knowledge-focused Recruiting nowThis study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tum…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Can Off-Label drugs help when standard cancer therapy fails? new study aims to find out
Knowledge-focused Recruiting nowThis study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Which IV fluid works best during surgery? new study aims to find out
Knowledge-focused Recruiting nowThis study looks at how well different fluids (albumin and Ringer's solution) increase blood volume during laparoscopic surgery. About 60 adults having abdominal surgery will receive one of three fluid types. The goal is to see which fluid keeps the heart and blood vessels workin…
Phase 4 • Sponsor: Joachim Zdolsek • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:27 UTC
-
Blood particles may predict chemo nerve pain
Knowledge-focused Recruiting nowThis study is testing whether tiny particles in the blood, called extracellular vesicles, can predict nerve damage caused by chemotherapy. Researchers will follow 120 adults with various cancers who are receiving specific chemo drugs. Participants give blood samples and answer qu…
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
New study tracks Real-World care for sinonasal and Skull-Base tumours
Knowledge-focused Recruiting nowThis study is observing 120 patients with sinonasal or skull-base tumours at a specialist ear, nose, and throat centre. Researchers are tracking how these conditions are managed, what the outcomes are, and how patients' quality of life changes. The goal is to better understand cu…
Sponsor: University Medical Centre Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New device tracks hormone rhythms every 20 minutes in adrenal tumor patients
Knowledge-focused Recruiting nowThis study is looking at how cortisol and other steroid hormones are produced over 24 hours in people with adrenal tumors. Researchers will use a special device called U-RHYTHM to take fluid samples every 20 minutes for up to 48 hours. The goal is to compare hormone patterns betw…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
AI translates doctor speak for cancer patients
Knowledge-focused Recruiting nowThis study tests whether using artificial intelligence (AI) to rewrite medical discharge letters into plain language helps cancer patients better understand their diagnosis, treatment, and next steps. About 150 adults with blood cancer or other cancers will be randomly assigned t…
Sponsor: Technical University of Munich • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New study tracks memory loss in kids after brain radiation
Knowledge-focused Recruiting nowThis study looks at how radiation to the brain affects memory in children who had a brain tumor. Researchers will test memory and thinking skills in 130 children ages 4 to 12, starting 2 years after radiation and again 2 years later. The goal is to learn which parts of the brain …
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Heart hole linked to stroke risk in lung clot patients?
Knowledge-focused Recruiting nowThis study looks at whether people who have a blood clot in the lungs (pulmonary embolism) are more likely to have a stroke if they also have a small hole in their heart (called a PFO). About 1 in 4 people have this hole, which can let a clot travel to the brain. Researchers will…
Sponsor: Tufts Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Massive study aims to predict brain surgery success
Knowledge-focused Recruiting nowThis study is gathering information from 4500 people who have or will have brain surgery for conditions like aneurysms, tumors, epilepsy, and Parkinson's disease. The goal is to find patterns that help doctors predict how well someone will recover. By standardizing how outcomes a…
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
New catheter study tracks targeted chemo delivery for solid tumors
Knowledge-focused Recruiting nowThis study is collecting information from 1,000 people with solid tumors who receive chemotherapy through a special catheter called RenovoCath, which delivers drugs directly to the tumor site. Researchers are tracking safety, side effects, and survival over time. The goal is to l…
Sponsor: RenovoRx • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
New study tracks immunotherapy patients to uncover Real-World insights
Knowledge-focused Recruiting nowThis study is creating a detailed database of 651 adults with solid tumors who are starting immunotherapy. Researchers will collect medical and lab information over 5 years to see how well these treatments work in everyday practice. The goal is to learn more about outcomes like s…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Could a simple Height-Based adjustment make tumor ablation safer?
Knowledge-focused Recruiting nowThis study looks at how to set the breathing machine (jet ventilator) during a procedure that destroys tumors with heat or cold. The goal is to find the best air pressure setting to keep patients breathing well while the doctor works precisely. About 560 adults having tumor ablat…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
1,000 patients to be tracked after brain and spine procedures – no new drug, just data
Knowledge-focused Recruiting nowThis study will follow 1,000 people of all ages who are having endovascular procedures (minimally invasive treatments through blood vessels) for brain or spinal conditions like aneurysms or abnormal blood vessels. Researchers will record complications, recovery, and changes in th…
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New registry to monitor ion beam therapy results
Knowledge-focused Recruiting nowThis registry study is collecting data from 2,800 cancer patients treated with ion beam therapy (protons and carbon ions) at MedAustron. Researchers will track tumor response, survival, side effects, and quality of life over time. The goal is to better understand the real-world b…
Sponsor: EBG MedAustron GmbH • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Lab-Grown tumor avatars could pick the right cancer drug for each patient
Knowledge-focused Recruiting nowThis study tests a personalized approach for patients with advanced liver or colorectal cancers that no longer respond to standard treatments. Doctors take a small sample of the tumor, grow it in the lab as 3D 'organoids', and test different drugs on them to see which works best.…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
AI may predict heart risk in cancer patients
Knowledge-focused Recruiting nowThis study aims to develop a machine learning tool to predict heart damage in 600 cancer patients receiving certain chemotherapy drugs (anthracyclines or HER2-targeted therapies). Researchers will collect data over one year to see who develops heart problems. The goal is to creat…
Sponsor: University Hospital, Caen • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Scientists hunt for immune clues in rare salivary gland cancers
Knowledge-focused Recruiting nowThis study is for 300 people with salivary gland tumors (both cancerous and non-cancerous) to learn how the immune system reacts to these rare cancers. Researchers will collect tumor tissue and blood samples before and after treatment to find immune markers that might predict how…
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
New study tracks pregnancy dangers in rare vascular conditions
Knowledge-focused Recruiting nowThis study follows 400 pregnant women with rare blood vessel diseases (like HHT, Marfan syndrome, or lymphedema) to learn about serious pregnancy complications. Researchers will ask participants about their health during pregnancy and for 12 months after birth. The goal is to gat…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New platform aims to predict which cancer treatments will work
Knowledge-focused Recruiting nowThis study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Hysterectomy tool may impact sex life – new study investigates
Knowledge-focused Recruiting nowThis study looks at whether using a uterine manipulator during hysterectomy changes sexual function three months after surgery. Sixty women having a hysterectomy for non-cancer reasons will be randomly assigned to have the surgery with or without the tool. The main goal is to com…
Sponsor: Erkan Gol • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Ultrasound clues to adenomyosis pain and bleeding
Knowledge-focused Recruiting nowThis study looks at 1,000 women to see how ultrasound features of adenomyosis (a condition where the uterine lining grows into the muscle wall) match up with their symptoms like pain and heavy bleeding. Participants get one routine ultrasound and fill out a symptom questionnaire.…
Sponsor: Swiss GO Trial Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
20,000 cancer patients to get genetic profiling in hunt for new treatments
Knowledge-focused Recruiting nowThis study will collect blood and tumor samples from 20,000 adults with solid tumors to perform detailed genetic analysis. The goal is to find how many patients have at least one genetic change that could be targeted by existing or experimental therapies. This is a research study…
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New scans may spot heart trouble early in young cancer survivors
Knowledge-focused Recruiting nowThis study tests whether newer imaging techniques like special ultrasound and MRI can detect heart damage earlier in children, adolescents, and young adults who have had cancer treatment. Researchers will follow 400 participants to see how many develop heart problems. The goal is…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Researchers track Long-Term outcomes after brain AVM treatment
Knowledge-focused Recruiting nowThis study follows 1000 adults who have had embolization for brain arteriovenous malformations (AVMs). The goal is to collect standardized long-term data, such as how well the AVM remains blocked over time. Currently, follow-up practices vary widely, so this research aims to impr…
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Proton therapy under the microscope: huge study aims to prove its worth
Knowledge-focused Recruiting nowThis study is gathering information from 500 cancer patients treated with proton therapy, a type of radiation that may cause fewer side effects than standard radiation. Researchers want to see how well it works in everyday practice and track any side effects. The goal is to build…
Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Gene hunt: can DNA predict brain bleed risk?
Knowledge-focused Recruiting nowThis study looks at the genes of 300 people with brain or spinal cord arteriovenous malformations (AVMs) to see if certain mutations affect the risk of bleeding. Researchers will compare genetic information with medical outcomes to better understand why some AVMs cause serious pr…
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Immune clues could predict radiotherapy success
Knowledge-focused Recruiting nowThis study aims to find immune system markers that can predict how well a cancer patient responds to radiotherapy. Researchers will analyze blood samples from 40 adults who have already completed radiotherapy without major side effects. The goal is to personalize future cancer tr…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
AI takes on mysterious uterine tumors: a new hope for accurate diagnosis
Knowledge-focused Recruiting nowThis study is testing whether artificial intelligence can help doctors better classify and predict the behavior of rare smooth muscle tumors of the uterus, including those that are hard to diagnose (called STUMP). Researchers will train AI models on digital images of tumor tissue…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Researchers track Long-Term risks of viral cancer therapy
Knowledge-focused Recruiting nowThis study watches 50 people who already received a replimune oncolytic immunotherapy for cancers like melanoma or liver cancer. The goal is to check for any delayed side effects over 5 years. No new treatment is given—just regular check-ins to see how patients are doing.
Sponsor: Replimune, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Researchers hunt for best test to spot hidden hormone problem in adrenal tumors
Knowledge-focused Recruiting nowThis study looks at 20 adults with adrenal tumors (incidentalomas) to find the most accurate tests for detecting mild autonomous cortisol secretion (MACS), a condition where the tumor releases extra cortisol. Participants will provide blood, saliva, and urine samples and undergo …
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
New MRI technique could prevent unnecessary brain surgery for benign tumor
Knowledge-focused Recruiting nowThis study tests whether ultra-high-resolution MRI can more clearly identify a rare, benign brain tumor called MVNT. Currently, standard MRI may leave the diagnosis uncertain, leading some patients to undergo surgery for a harmless growth. Researchers will scan 33 adults with sus…
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Can a patch catch hidden heart risks better than standard ECGs?
Knowledge-focused Recruiting nowThis study compares a continuous heart-monitoring patch with standard electrocardiograms (ECGs) in 60 adults receiving cancer drugs that can cause dangerous heart rhythm changes. The goal is to see if the patch detects problems more accurately and consistently. Participants will …
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Scientists probe aging cells in fibroids for clues to new treatments
Knowledge-focused Recruiting nowThis study at Johns Hopkins University is looking at how aging cells (senescent cells) contribute to uterine fibroids, which are non-cancerous growths in the uterus. Researchers will analyze tissue samples from 150 women with fibroids to map these cells and their signals. The goa…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Blood test may predict dangerous immunotherapy reactions
Knowledge-focused Recruiting nowThis study aims to find a way to predict which cancer patients will experience side effects from immunotherapy. These side effects happen when the immune system attacks healthy tissues, similar to autoimmune diseases. Researchers will collect blood samples from 300 cancer patient…
Sponsor: Hospital Universitario Araba • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Cancer blood test research launches at princess margaret
Knowledge-focused Recruiting nowThis study aims to create a large collection of blood samples from 2,500 people with or at high risk for cancer. Researchers will use these samples to study liquid biopsies, which are blood tests that may help detect cancer, track treatment response, and spot recurrence. Particip…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Gene-Matching trial aims to outsmart cancer by pairing mutations with drugs
Knowledge-focused Recruiting nowThis study is analyzing tumor and blood samples from 10,000 adults with advanced solid tumors or blood cancers to find genetic changes that can be targeted by existing drugs. The goal is to see how often these 'actionable' alterations occur and to guide patients toward personaliz…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Urine clue may spot kidney danger in ICU patients
Knowledge-focused Recruiting nowThis study aims to find out if a urine test can predict acute kidney failure in intensive care patients. Researchers will measure certain substances in the urine that reflect how the body produces NAD+, a key molecule for cell energy. If successful, this could help doctors identi…
Sponsor: Ramsay Générale de Santé • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
10,000-Patient study monitors BALT medical devices in Real-World use
Knowledge-focused Recruiting nowThis study is collecting information from up to 10,000 people who receive BALT medical devices for conditions like brain aneurysms, stroke, and blocked arteries. Researchers will track how well the devices work and if any safety issues arise during routine care. The goal is to ga…
Sponsor: Balt Extrusion • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:47 UTC
-
Massive study aims to unlock Cancer's immune secrets
Knowledge-focused Recruiting nowThis study will collect blood and tumor samples from 1,100 people with various cancers, including head and neck, ovarian, cervical, lung, and brain cancers. Researchers want to learn how immune cells called T cells behave in these tumors. The goal is to better understand why some…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:24 UTC
-
Shedding pounds, easing back pain? new study investigates spine changes after weight loss surgery
Knowledge-focused Recruiting nowThis study follows 80 obese patients who are planning to have bariatric surgery. Researchers will measure back pain, spine alignment, and spinal fat before and after significant weight loss. The goal is to understand how losing a lot of weight affects the spine and whether it hel…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:07 UTC
-
Robot vs. laparoscopic: which pancreas surgery is better?
Knowledge-focused Recruiting nowThis study compares two minimally invasive surgical techniques—laparoscopic and robot-assisted—for removing the left side of the pancreas in people with benign or pre-cancerous growths. About 256 participants will be randomly assigned to one of the two procedures. The goal is to …
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:56 UTC
-
Can protein protect muscles during radiation? new study investigates
Knowledge-focused Recruiting nowThis study looks at how much protein cancer patients eat before, during, and after radiotherapy, and whether that affects their muscle mass and quality of life. Researchers will track 175 adults aged 45 and older undergoing radiation for various tumors. The goal is to understand …
Sponsor: Charite University, Berlin, Germany • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:47 UTC